[S02DA03, antipyrine, The metabolism of Pomalidomide can be decreased when combined with Antipyrine.]
[B01AD01, streptokinase, The risk or severity of bleeding can be increased when Streptokinase is combined with Pomalidomide.]
[J01GA01, streptomycin, Pomalidomide may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[L04AA04, rabbit anti-human T-lymphocyte globulin, The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pomalidomide.]
[L01AD04, streptozocin, The risk or severity of adverse effects can be increased when Streptozocin is combined with Pomalidomide.]
[L04AA27, fingolimod, Pomalidomide may increase the immunosuppressive activities of Fingolimod.]
[M03AB01, succinylcholine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Pomalidomide.]
[A02BX02, sucralfate, Sucralfate may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[J01CG01, sulbactam, Pomalidomide may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01EC02, sulfadiazine, Sulfadiazine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[J01EC01, sulfamethoxazole, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Pomalidomide.]
[M04AB02, sulfinpyrazone, The metabolism of Pomalidomide can be increased when combined with Sulfinpyrazone.]
[M01AB02, sulindac, Sulindac may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N05AL01, sulpiride, The risk or severity of adverse effects can be increased when Sulpiride is combined with Pomalidomide.]
[N03AX03, sulthiame, The risk or severity of adverse effects can be increased when Sulthiame is combined with Pomalidomide.]
[M01AX04, apazone, Azapropazone may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[L01BB02, mercaptopurine, The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Pomalidomide.]
[N06DA01, tacrine, The metabolism of Pomalidomide can be decreased when combined with Tacrine.]
[L02BA01, tamoxifen, The serum concentration of Pomalidomide can be increased when it is combined with Tamoxifen.]
[N05CD07, temazepam, The risk or severity of adverse effects can be increased when Temazepam is combined with Pomalidomide.]
[L01CB02, teniposide, The metabolism of Pomalidomide can be decreased when combined with Teniposide.]
[R03CC03, terbutaline, Terbutaline may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[B01AE07, dabigatran etexilate, The serum concentration of Pomalidomide can be increased when it is combined with Dabigatran etexilate.]
[G03BA03, testosterone, The metabolism of Pomalidomide can be increased when combined with Testosterone.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Pomalidomide is combined with Tetracaine.]
[S03AA02, tetracycline, The metabolism of Pomalidomide can be decreased when combined with Tetracycline.]
[J01DI02, ceftaroline fosamil, Ceftaroline fosamil may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N05AE05, lurasidone, The risk or severity of adverse effects can be increased when Lurasidone is combined with Pomalidomide.]
[A04AD10, dronabinol, Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Pomalidomide.]
[L04AX02, thalidomide, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03DA07, theobromine, Theobromine may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[R03DA04, theophylline, The metabolism of Pomalidomide can be decreased when combined with Theophylline.]
[P02CA02, thiabendazole, The metabolism of Pomalidomide can be decreased when combined with Thiabendazole.]
[L01XX41, eribulin, The risk or severity of adverse effects can be increased when Eribulin is combined with Pomalidomide.]
[R06AD03, thiethylperazine, The risk or severity of adverse effects can be increased when Thiethylperazine is combined with Pomalidomide.]
[L01AC01, thiotepa, The risk or severity of adverse effects can be increased when Thiotepa is combined with Pomalidomide.]
[L01BB03, thioguanine, The risk or severity of adverse effects can be increased when Tioguanine is combined with Pomalidomide.]
[N05CA19, thiopental, The risk or severity of adverse effects can be increased when Thiopental is combined with Pomalidomide.]
[N05AB08, thioproperazine, The risk or severity of adverse effects can be increased when Thioproperazine is combined with Pomalidomide.]
[N05AC02, thioridazine, The risk or severity of adverse effects can be increased when Thioridazine is combined with Pomalidomide.]
[N05AF04, thiothixene, The risk or severity of adverse effects can be increased when Thiothixene is combined with Pomalidomide.]
[G04BE06, moxisylyte, Pomalidomide may decrease the excretion rate of Moxisylyte which could result in a higher serum level.]
[N05AL03, tiapride, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Tiapride.]
[B01AC05, ticlopidine, The metabolism of Pomalidomide can be decreased when combined with Ticlopidine.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Tilidine.]
[S01ED01, timolol, Timolol may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[P01AB02, tinidazole, Tinidazole may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[S01AA12, tobramycin, Pomalidomide may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, Tolazamide may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[V04CA01, tolbutamide, Tolbutamide may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[M02AA21, tolmetin, Tolmetin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[M03BX04, tolperisone, The risk or severity of adverse effects can be increased when Tolperisone is combined with Pomalidomide.]
[N02AX02, tramadol, The risk or severity of CNS depression can be increased when Pomalidomide is combined with Tramadol.]
[N06AF04, tranylcypromine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Pomalidomide.]
[C01DX11, trapidil, The risk or severity of bleeding can be increased when Trapidil is combined with Pomalidomide.]
[N06AX05, trazodone, The serum concentration of Pomalidomide can be decreased when it is combined with Trazodone.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Tretinoin is combined with Pomalidomide.]
[S01BA05, triamcinolone, The metabolism of Pomalidomide can be increased when combined with Triamcinolone.]
[C03DB02, triamterene, Triamterene may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD05, triazolam, The risk or severity of adverse effects can be increased when Triazolam is combined with Pomalidomide.]
[C03AA06, trichlormethiazide, Trichlormethiazide may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[A03AB12, mepenzolate, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[A16AX12, trientine, Triethylenetetramine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N05AB06, trifluoperazine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Pomalidomide.]
[S01AD02, trifluridine, The risk or severity of adverse effects can be increased when Trifluridine is combined with Pomalidomide.]
[N05AD02, trifluperidol, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Trifluperidol.]
[N05AA05, triflupromazine, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.]
[D07AC02, fluclorolone, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Fluclorolone.]
[N04AA01, trihexyphenidyl, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.]
[R03BA07, mometasone, The metabolism of Pomalidomide can be increased when combined with Mometasone.]
[A03AA05, trimebutine, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of adverse effects can be increased when Alimemazine is combined with Pomalidomide.]
[N03AC02, trimethadione, The risk or severity of adverse effects can be increased when Trimethadione is combined with Pomalidomide.]
[J01EA01, trimethoprim, Trimethoprim may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N06AA06, trimipramine, The risk or severity of adverse effects can be increased when Trimipramine is combined with Pomalidomide.]
[R06AX07, triprolidine, The risk or severity of adverse effects can be increased when Triprolidine is combined with Pomalidomide.]
[A03BB01, butylscopolamine, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[J01FA08, troleandomycin, The metabolism of Pomalidomide can be decreased when combined with Troleandomycin.]
[N06AX24, vilazodone, The risk or severity of adverse effects can be increased when Vilazodone is combined with Pomalidomide.]
[N06AX02, tryptophan, The risk or severity of adverse effects can be increased when Tryptophan is combined with Pomalidomide.]
[M03AA02, tubocurarine, The risk or severity of adverse effects can be increased when Tubocurarine is combined with Pomalidomide.]
[R03DX07, roflumilast, Roflumilast may increase the immunosuppressive activities of Pomalidomide.]
[L04AA26, belimumab, The risk or severity of adverse effects can be increased when Belimumab is combined with Pomalidomide.]
[L01FX04, ipilimumab, Ipilimumab may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[L01EX04, vandetanib, The serum concentration of Pomalidomide can be increased when it is combined with Vandetanib.]
[R02AA14, oxyquinoline, Pomalidomide may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[L02BX03, abiraterone, The serum concentration of Pomalidomide can be increased when it is combined with Abiraterone.]
[A10BH05, linagliptin, The serum concentration of Pomalidomide can be increased when it is combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Pomalidomide can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Pomalidomide can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The metabolism of Pomalidomide can be decreased when combined with Rilpivirine.]
[B01AD04, urokinase, The risk or severity of bleeding can be increased when Urokinase is combined with Pomalidomide.]
[S01AA28, vancomycin, Pomalidomide may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[L04AA28, belatacept, The risk or severity of adverse effects can be increased when Belatacept is combined with Pomalidomide.]
[N03AX21, ezogabine, The risk or severity of adverse effects can be increased when Ezogabine is combined with Pomalidomide.]
[B01AF01, rivaroxaban, The serum concentration of Pomalidomide can be increased when it is combined with Rivaroxaban.]
[R03AC18, indacaterol, The serum concentration of Pomalidomide can be increased when it is combined with Indacaterol.]
[B01AC24, ticagrelor, The serum concentration of Pomalidomide can be increased when it is combined with Ticagrelor.]
[C08DA01, verapamil, The serum concentration of Pomalidomide can be increased when it is combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Pomalidomide can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Pomalidomide can be increased when combined with Vinblastine.]
[L01CA02, vincristine, The risk or severity of adverse effects can be increased when Vincristine is combined with Pomalidomide.]
[L01CA03, vindesine, The risk or severity of adverse effects can be increased when Vindesine is combined with Pomalidomide.]
[B03BA01, vitamin B12, The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Pomalidomide.]
[A11HA03, vitamin E, The metabolism of Pomalidomide can be increased when combined with Vitamin E.]
[B01AA03, warfarin, The metabolism of Pomalidomide can be increased when combined with Warfarin.]
[C03BA10, xipamide, Xipamide may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF01, zidovudine, The risk or severity of adverse effects can be increased when Zidovudine is combined with Pomalidomide.]
[N05AF05, zuclopenthixol, The metabolism of Pomalidomide can be decreased when combined with Zuclopenthixol.]
[J05AE02, indinavir, The metabolism of Pomalidomide can be decreased when combined with Indinavir.]
[N03AX14, levetiracetam, The risk or severity of adverse effects can be increased when Levetiracetam is combined with Pomalidomide.]
[L01EC01, vemurafenib, The serum concentration of Pomalidomide can be increased when it is combined with Vemurafenib.]
[L01FX05, brentuximab vedotin, The metabolism of Pomalidomide can be decreased when combined with Brentuximab vedotin.]
[M05BA05, tiludronic acid, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Pomalidomide is combined with Tiludronic acid.]
[B06AC02, icatibant, Icatibant may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[L01ED01, crizotinib, The metabolism of Pomalidomide can be decreased when combined with Crizotinib.]
[B01AE01, desirudin, The risk or severity of bleeding can be increased when Lepirudin is combined with Pomalidomide.]
[R03DC01, zafirlukast, The metabolism of Pomalidomide can be decreased when combined with Zafirlukast.]
[A02BC04, rabeprazole, Rabeprazole may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[M05BA06, ibandronic acid, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Pomalidomide is combined with Ibandronate.]
[J01MA13, trovafloxacin, The metabolism of Pomalidomide can be decreased when combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Ziprasidone.]
[G03AC10, drospirenone, The metabolism of Pomalidomide can be decreased when combined with Drospirenone.]
[V03AC02, deferiprone, Deferiprone may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[L04AA34, alemtuzumab, The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pomalidomide.]
[N02BA01, aspirin, The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Pomalidomide.]
[L01EJ01, ruxolitinib, The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Pomalidomide.]
[G04BD07, tolterodine, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.]
[J01DH04, doripenem, Doripenem may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[L03AB11, peginterferon alfa-2a, The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Pomalidomide.]
[L01FA01, rituximab, The risk or severity of adverse effects can be increased when Rituximab is combined with Pomalidomide.]
[J02AC03, voriconazole, The metabolism of Pomalidomide can be decreased when combined with Voriconazole.]
[M03AC04, atracurium, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Atracurium.]
[S01FA01, atropine, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[M01CB03, auranofin, Auranofin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[L01EK01, axitinib, The metabolism of Pomalidomide can be decreased when combined with Axitinib.]
[R07AX02, ivacaftor, The serum concentration of Pomalidomide can be increased when it is combined with Ivacaftor.]
[H02AB11, prednylidene, The metabolism of Pomalidomide can be increased when combined with Prednylidene.]
[B03XA04, peginesatide, The risk or severity of Thrombosis can be increased when Peginesatide is combined with Pomalidomide.]
[L01BC07, azacitidine, The risk or severity of adverse effects can be increased when Azacitidine is combined with Pomalidomide.]
[L04AX01, azathioprine, The risk or severity of adverse effects can be increased when Azathioprine is combined with Pomalidomide.]
[L01BC05, gemcitabine, The risk or severity of adverse effects can be increased when Gemcitabine is combined with Pomalidomide.]
[J01DF01, aztreonam, Aztreonam may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[R02AB04, bacitracin, Bacitracin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Pomalidomide.]
[M03BX01, baclofen, Baclofen may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Pomalidomide.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pomalidomide.]
[A08AA11, lorcaserin, The risk or severity of adverse effects can be increased when Lorcaserin is combined with Pomalidomide.]
[G04BD12, mirabegron, The serum concentration of Pomalidomide can be increased when it is combined with Mirabegron.]
[L01XG02, carfilzomib, The serum concentration of Pomalidomide can be increased when it is combined with Carfilzomib.]
[V03AX03, cobicistat, The metabolism of Pomalidomide can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Pomalidomide can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Pomalidomide can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The metabolism of Pomalidomide can be decreased when combined with Bosutinib.]
[L04AA31, teriflunomide, The serum concentration of Pomalidomide can be decreased when it is combined with Teriflunomide.]
[B01AX01, defibrotide, The risk or severity of bleeding can be increased when Defibrotide is combined with Pomalidomide.]
[L04AA22, abetimus, The risk or severity of adverse effects can be increased when Abetimus is combined with Pomalidomide.]
[H02AA01, aldosterone, The risk or severity of adverse effects can be increased when Aldosterone is combined with Pomalidomide.]
[L01EX05, regorafenib, The serum concentration of Pomalidomide can be increased when it is combined with Regorafenib.]
[N05CA04, barbital, The metabolism of Pomalidomide can be increased when combined with Barbital.]
[D02BA02, octinoxate, Pomalidomide may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[J05AE04, nelfinavir, The metabolism of Pomalidomide can be decreased when combined with Nelfinavir.]
[L01AA09, bendamustine, The risk or severity of adverse effects can be increased when Bendamustine is combined with Pomalidomide.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.]
[N04BD02, rasagiline, The risk or severity of adverse effects can be increased when Rasagiline is combined with Pomalidomide.]
[A03FA09, mosapride, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Mosapride.]
[N06DA02, donepezil, The risk or severity of adverse effects can be increased when Donepezil is combined with Pomalidomide.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.]
[L04AA29, tofacitinib, Pomalidomide may increase the immunosuppressive activities of Tofacitinib.]
[N02CC03, zolmitriptan, The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Pomalidomide.]
[R06AC06, thonzylamine, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.]
[V09IX04, fluorodeoxyglucose F18, Pomalidomide may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[N01AA01, ethyl ether, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Diethyl ether.]
[H01CB05, pasireotide, The metabolism of Pomalidomide can be decreased when combined with Pasireotide.]
[G04BE03, sildenafil, The serum concentration of Pomalidomide can be increased when it is combined with Sildenafil.]
[V08CA11, gadofosveset, Gadofosveset trisodium may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[L01EA05, ponatinib, The serum concentration of Pomalidomide can be increased when it is combined with Ponatinib.]
[B01AF02, apixaban, The serum concentration of Pomalidomide can be increased when it is combined with Apixaban.]
[A16AX08, teduglutide, Teduglutide may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[C10AX12, lomitapide, The serum concentration of Pomalidomide can be increased when it is combined with Lomitapide.]
[A10BH04, alogliptin, Alogliptin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Pomalidomide can be increased when combined with Glycerol phenylbutyrate.]
[C03AA01, bendroflumethiazide, Bendroflumethiazide may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Antilymphocyte immunoglobulin (horse).]
[S01AA13, fusidic acid, The metabolism of Pomalidomide can be decreased when combined with Fusidic acid.]
[J01MB04, pipemidic acid, The metabolism of Pomalidomide can be decreased when combined with Pipemidic acid.]
[M05BA03, pamidronic acid, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Pomalidomide is combined with Pamidronic acid.]
[N02BA10, benorilate, Benorilate may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N05AD07, benperidol, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Benperidol.]
[A10BK02, canagliflozin, The serum concentration of Pomalidomide can be increased when it is combined with Canagliflozin.]
[L04AX07, dimethyl fumarate, The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Pomalidomide.]
[J01MA15, gemifloxacin, The metabolism of Pomalidomide can be decreased when combined with Gemifloxacin.]
[S01AE07, moxifloxacin, The metabolism of Pomalidomide can be decreased when combined with Moxifloxacin.]
[A06AX06, tegaserod, The metabolism of Pomalidomide can be decreased when combined with Tegaserod.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Pomalidomide is combined with Benzocaine.]
[L03AA12, ancestim, Pomalidomide may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, Celecoxib may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N02CC02, naratriptan, The risk or severity of adverse effects can be increased when Naratriptan is combined with Pomalidomide.]
[L04AA18, everolimus, The serum concentration of Pomalidomide can be increased when it is combined with Everolimus.]
[N04AC01, benztropine, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.]
[L01EC02, dabrafenib, The serum concentration of Pomalidomide can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, Benzydamine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[L01EE01, trametinib, Pomalidomide may decrease the excretion rate of Trametinib which could result in a higher serum level.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Pomalidomide is combined with Benzyl alcohol.]
[V09AX05, florbetapir F-18, Pomalidomide may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[L01EB03, afatinib, The serum concentration of Pomalidomide can be increased when it is combined with Afatinib.]
[N06AX28, levomilnacipran, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Levomilnacipran.]
[J05AJ03, dolutegravir, The serum concentration of Pomalidomide can be increased when it is combined with Dolutegravir.]
[C02KX05, riociguat, The serum concentration of Pomalidomide can be increased when it is combined with Riociguat.]
[L03AA14, lipegfilgrastim, Pomalidomide may increase the myelosuppressive activities of Lipegfilgrastim.]
[A10BJ03, lixisenatide, Pomalidomide may decrease the excretion rate of Lixisenatide which could result in a higher serum level.]
[C02KX04, macitentan, Pomalidomide may decrease the excretion rate of Macitentan which could result in a higher serum level.]
[L01EL01, ibrutinib, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Ibrutinib.]
[N06AX26, vortioxetine, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Vortioxetine.]
[G03AC08, etonogestrel, Etonogestrel may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N03AF04, eslicarbazepine, The metabolism of Pomalidomide can be increased when combined with Eslicarbazepine.]
[J05AP05, simeprevir, The serum concentration of Pomalidomide can be increased when it is combined with Simeprevir.]
[J05AP08, sofosbuvir, The serum concentration of Pomalidomide can be increased when it is combined with Sofosbuvir.]
[N03AG04, vigabatrin, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Pomalidomide.]
[A10BK01, dapagliflozin, The metabolism of Pomalidomide can be decreased when combined with Dapagliflozin.]
[C01CA27, droxidopa, Droxidopa may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N05CH03, tasimelteon, The metabolism of Pomalidomide can be decreased when combined with Tasimelteon.]
[A16AA07, metreleptin, The metabolism of Pomalidomide can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Pomalidomide can be increased when combined with Apremilast.]
[L02BG02, formestane, The metabolism of Pomalidomide can be increased when combined with Formestane.]
[S03BA03, betamethasone, The metabolism of Pomalidomide can be increased when combined with Betamethasone.]
[S01ED02, betaxolol, The metabolism of Pomalidomide can be decreased when combined with Betaxolol.]
[B01AE03, argatroban, The risk or severity of bleeding can be increased when Argatroban is combined with Pomalidomide.]
[V03AB34, fomepizole, Fomepizole may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[L04AC11, siltuximab, The metabolism of Pomalidomide can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The metabolism of Pomalidomide can be decreased when combined with Ceritinib.]
[B01AC26, vorapaxar, The serum concentration of Pomalidomide can be increased when it is combined with Vorapaxar.]
[L04AA33, vedolizumab, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Vedolizumab.]
[A03BA03, hyoscyamine, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.]
[B01AA07, acenocoumarol, The metabolism of Pomalidomide can be decreased when combined with Acenocoumarol.]
[L01XH04, belinostat, The risk or severity of adverse effects can be increased when Belinostat is combined with Pomalidomide.]
[L01EM01, idelalisib, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Idelalisib.]
[N01AX05, alfaxalone, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Alfaxalone.]
[L03AB13, peginterferon beta-1a, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Peginterferon beta-1a.]
[V08AA01, diatrizoic acid, Diatrizoate may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[D11AA01, glycopyrronium, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.]
[V08AA04, iothalamic acid, Diatrizoate may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N05CM19, suvorexant, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[A16AX10, eliglustat, The serum concentration of Pomalidomide can be increased when it is combined with Eliglustat.]
[J01XA05, oritavancin, The metabolism of Pomalidomide can be increased when combined with Oritavancin.]
[S01AA15, dihydrostreptomycin, Dihydrostreptomycin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N05AA04, acepromazine, The risk or severity of adverse effects can be increased when Acepromazine is combined with Pomalidomide.]
[L01BC08, decitabine, The risk or severity of adverse effects can be increased when Decitabine is combined with Pomalidomide.]
[N04AA02, biperiden, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Biperiden.]
[L04AX05, pirfenidone, The risk or severity of adverse effects can be increased when Pirfenidone is combined with Pomalidomide.]
[L01EX09, nintedanib, The metabolism of Pomalidomide can be decreased when combined with Nintedanib.]
[S03AA06, gentamicin, Pomalidomide may decrease the excretion rate of Gentamicin which could result in a higher serum level.]
[L01FX07, blinatumomab, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Blinatumomab.]
[J05AP09, dasabuvir, The serum concentration of Pomalidomide can be increased when it is combined with Dasabuvir.]
[L01XK01, olaparib, The metabolism of Pomalidomide can be decreased when combined with Olaparib.]
[B01AA01, dicumarol, The risk or severity of bleeding can be increased when Dicoumarol is combined with Pomalidomide.]
[B01AF03, edoxaban, The serum concentration of Pomalidomide can be increased when it is combined with Edoxaban.]
[N06AX11, mirtazapine, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Pomalidomide can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The serum concentration of Pomalidomide can be increased when it is combined with Palbociclib.]
[L01EX08, lenvatinib, The serum concentration of Pomalidomide can be increased when it is combined with Lenvatinib.]
[L01XH03, panobinostat, The risk or severity of adverse effects can be increased when Panobinostat is combined with Pomalidomide.]
[J05AP07, daclatasvir, The serum concentration of Pomalidomide can be increased when it is combined with Daclatasvir.]
[N02BE01, acetaminophen, The metabolism of Pomalidomide can be increased when combined with Acetaminophen.]
[L01DC01, bleomycin, The risk or severity of adverse effects can be increased when Bleomycin is combined with Pomalidomide.]
[A03AA09, difemerine, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[B01AA11, tioclomarol, The risk or severity of bleeding can be increased when Tioclomarol is combined with Pomalidomide.]
[J05AF08, adefovir dipivoxil, Adefovir dipivoxil may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[J05AP06, asunaprevir, The serum concentration of Pomalidomide can be increased when it is combined with Asunaprevir.]
[B01AC25, cangrelor, The risk or severity of bleeding can be increased when Cangrelor is combined with Pomalidomide.]
[N05AX16, brexpiprazole, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Brexpiprazole.]
[A04AD14, rolapitant, The serum concentration of Pomalidomide can be increased when it is combined with Rolapitant.]
[G02CX02, flibanserin, The serum concentration of Pomalidomide can be increased when it is combined with Flibanserin.]
[N05AX15, cariprazine, The risk or severity of adverse effects can be increased when Cariprazine is combined with Pomalidomide.]
[M02AA25, aceclofenac, Aceclofenac may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[M01AB11, acemetacin, Acemetacin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[S01EC01, acetazolamide, The metabolism of Pomalidomide can be decreased when combined with Acetazolamide.]
[N05AB07, acetophenazine, The risk or severity of adverse effects can be increased when Acetophenazine is combined with Pomalidomide.]
[V03AB37, idarucizumab, Pomalidomide may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[L01CX01, trabectedin, The risk or severity of adverse effects can be increased when Trabectedin is combined with Pomalidomide.]
[R03DX09, mepolizumab, The risk or severity of adverse effects can be increased when Mepolizumab is combined with Pomalidomide.]
[J02AC05, isavuconazole, The serum concentration of Pomalidomide can be increased when it is combined with Isavuconazole.]
[L01EB04, osimertinib, The serum concentration of Pomalidomide can be decreased when it is combined with Osimertinib.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Pomalidomide.]
[L01EE02, cobimetinib, The metabolism of Pomalidomide can be decreased when combined with Cobimetinib.]
[L01XG03, ixazomib, Pomalidomide may decrease the excretion rate of Ixazomib which could result in a higher serum level.]
[B01AC27, selexipag, The serum concentration of Pomalidomide can be increased when it is combined with Selexipag.]
[M04AB05, lesinurad, The metabolism of Pomalidomide can be increased when combined with Lesinurad.]
[J05AP10, elbasvir, The serum concentration of Pomalidomide can be increased when it is combined with Elbasvir.]
[J05AP11, grazoprevir, The serum concentration of Pomalidomide can be increased when it is combined with Grazoprevir.]
[N05CA05, aprobarbital, The metabolism of Pomalidomide can be increased when combined with Aprobarbital.]
[M01AE16, alminoprofen, Alminoprofen may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N03AX23, brivaracetam, The risk or severity of adverse effects can be increased when Brivaracetam is combined with Pomalidomide.]
[L04AC13, ixekizumab, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Ixekizumab.]
[L01XX52, venetoclax, The serum concentration of Pomalidomide can be increased when it is combined with Venetoclax.]
[N05BA08, bromazepam, The risk or severity of adverse effects can be increased when Bromazepam is combined with Pomalidomide.]
[N04BC01, bromocriptine, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Pomalidomide.]
[A02AD05, aluminum magnesium silicate, Pomalidomide may decrease the excretion rate of Almasilate which could result in a higher serum level.]
[A03AX08, alverine, The risk or severity of adverse effects can be increased when Alverine is combined with Pomalidomide.]
[R06AB01, brompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pomalidomide.]
[N06AA19, amineptin, The risk or severity of adverse effects can be increased when Amineptine is combined with Pomalidomide.]
[N05AX17, pimavanserin, The metabolism of Pomalidomide can be decreased when combined with Pimavanserin.]
[N06BX11, aniracetam, The risk or severity of adverse effects can be increased when Aniracetam is combined with Pomalidomide.]
[A05AA04, obeticholic acid, The risk or severity of adverse effects can be increased when Obeticholic acid is combined with Pomalidomide.]
[C03CA02, bumetanide, Bumetanide may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Pomalidomide is combined with Bupivacaine.]
[N07BC01, buprenorphine, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05BE01, buspirone, The risk or severity of adverse effects can be increased when Buspirone is combined with Pomalidomide.]
[L01AB01, busulfan, The risk or severity of adverse effects can be increased when Busulfan is combined with Pomalidomide.]
[L01XX27, arsenic trioxide, The serum concentration of Pomalidomide can be increased when it is combined with Arsenic trioxide.]
[M02AA03, clofezone, Rabeprazole may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N02AF01, butorphanol, The risk or severity of adverse effects can be increased when Butorphanol is combined with Pomalidomide.]
[S01GX07, azelastine, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[L01XK03, rucaparib, The metabolism of Pomalidomide can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The metabolism of Pomalidomide can be decreased when combined with Azithromycin.]
[L04AC12, brodalumab, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Brodalumab.]
[L01EF02, ribociclib, The metabolism of Pomalidomide can be decreased when combined with Ribociclib.]
[A07EC04, balsalazide, Balsalazide may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[R03DA08, bamifylline, The metabolism of Bamifylline can be decreased when combined with Pomalidomide.]
[L04AA36, ocrelizumab, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Ocrelizumab.]
[A06AH05, naldemedine, Pomalidomide may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, Pomalidomide may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.]
[N02BF02, pregabalin, The therapeutic efficacy of Pomalidomide can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Beclamide.]
[N06BC01, caffeine, The metabolism of Pomalidomide can be decreased when combined with Caffeine.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Pomalidomide is combined with Oxybuprocaine.]
[D05AX03, calcitriol, The metabolism of Pomalidomide can be increased when combined with Calcitriol.]
[P01CA02, benznidazole, Pomalidomide may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[L04AC01, daclizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Pomalidomide.]
[J01XX08, linezolid, The risk or severity of adverse effects can be increased when Linezolid is combined with Pomalidomide.]
[J05AF06, abacavir, Abacavir may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[J05AE09, tipranavir, The metabolism of Pomalidomide can be decreased when combined with Tipranavir.]
[N07XX13, valbenazine, Pomalidomide may decrease the excretion rate of Valbenazine which could result in a higher serum level.]
[L04AB02, infliximab, The metabolism of Pomalidomide can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Pomalidomide can be decreased when combined with Midostaurin.]
[N04BD03, safinamide, The risk or severity of adverse effects can be increased when Safinamide is combined with Pomalidomide.]
[L04AC14, sarilumab, The metabolism of Pomalidomide can be increased when combined with Sarilumab.]
[J01MA23, delafloxacin, Pomalidomide may decrease the excretion rate of Delafloxacin which could result in a higher serum level.]
[B01AF04, betrixaban, The serum concentration of Pomalidomide can be increased when it is combined with Betrixaban.]
[L04AC16, guselkumab, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Guselkumab.]
[D01AC10, bifonazole, The metabolism of Pomalidomide can be decreased when combined with Bifonazole.]
[L01BC06, capecitabine, The risk or severity of adverse effects can be increased when Capecitabine is combined with Pomalidomide.]
[L01XX59, enasidenib, The serum concentration of Pomalidomide can be increased when it is combined with Enasidenib.]
[L01EH02, neratinib, The serum concentration of Pomalidomide can be increased when it is combined with Neratinib.]
[L01FB01, inotuzumab ozogamicin, The serum concentration of Pomalidomide can be increased when it is combined with Inotuzumab ozogamicin.]
[L01XH01, vorinostat, The risk or severity of adverse effects can be increased when Vorinostat is combined with Pomalidomide.]
[L01EM02, copanlisib, The serum concentration of Copanlisib can be increased when it is combined with Pomalidomide.]
[L01EF03, abemaciclib, The serum concentration of Abemaciclib can be increased when it is combined with Pomalidomide.]
[C07AB07, bisoprolol, The serum concentration of Pomalidomide can be increased when it is combined with Bisoprolol.]
[J05AG03, efavirenz, The metabolism of Pomalidomide can be decreased when combined with Efavirenz.]
[J01DC10, cefprozil, Cefprozil may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N04AA11, bornaprine, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.]
[L04AC02, basiliximab, The risk or severity of adverse effects can be increased when Basiliximab is combined with Pomalidomide.]
[L01BA03, raltitrexed, The risk or severity of adverse effects can be increased when Raltitrexed is combined with Pomalidomide.]
[V03AF08, palifermin, The therapeutic efficacy of Palifermin can be decreased when used in combination with Pomalidomide.]
[N05AD06, bromperidol, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Bromperidol.]
[N05CD09, brotizolam, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Brotizolam.]
[C03DA03, canrenone, Canrenone may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA02, budesonide, The metabolism of Pomalidomide can be increased when combined with Budesonide.]
[C04AX20, buflomedil, The risk or severity of bleeding can be increased when Buflomedil is combined with Pomalidomide.]
[M01AB07, bumadizone, Bumadizone may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[L01EL02, acalabrutinib, The metabolism of Pomalidomide can be decreased when combined with Acalabrutinib.]
[N05CA03, butobarbital, The risk or severity of adverse effects can be increased when Butobarbital is combined with Pomalidomide.]
[J05AX18, letermovir, The metabolism of Pomalidomide can be decreased when combined with Letermovir.]
[N06AA15, butriptyline, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Butriptyline.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Pomalidomide is combined with Capsaicin.]
[A10BK04, ertugliflozin, Ertugliflozin may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CA08, butylvinal, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Vinylbital.]
[R06AX18, acrivastine, Pomalidomide may decrease the excretion rate of Acrivastine which could result in a higher serum level.]
[L02BB05, apalutamide, The serum concentration of Pomalidomide can be decreased when it is combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Pomalidomide can be increased when combined with Carbamazepine.]
[A03AA03, camylofine, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[R06AA08, carbinoxamine, The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Pomalidomide.]
[L03AB06, interferon alfa-n1, The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Pomalidomide.]
[C07AG02, carvedilol, The serum concentration of Pomalidomide can be increased when it is combined with Carvedilol.]
[B02BX09, fostamatinib, The metabolism of Pomalidomide can be decreased when combined with Fostamatinib.]
[N03AX24, cannabidiol, The risk or severity of adverse effects can be increased when Cannabidiol is combined with Pomalidomide.]
[B02BX08, avatrombopag, The serum concentration of Pomalidomide can be increased when it is combined with Avatrombopag.]
[L04AA37, baricitinib, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Baricitinib.]
[J01DE01, cefepime, Cefepime may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[J01DD10, cefetamet, Cefetamet may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[J01DD09, cefodizime, Cefodizime may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[J01DC11, ceforanide, Ceforanide may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[J01DD13, cefpodoxime, Cefpodoxime may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[L01EE03, binimetinib, The metabolism of Binimetinib can be decreased when combined with Pomalidomide.]
[J01DD14, ceftibuten, Ceftibuten may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[J01GB14, plazomicin, Pomalidomide may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[H01CC03, elagolix, The serum concentration of Pomalidomide can be increased when it is combined with Elagolix.]
[L01XX62, ivosidenib, The metabolism of Pomalidomide can be increased when combined with Ivosidenib.]
[A16AX14, migalastat, Migalastat may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N03AX17, stiripentol, The metabolism of Pomalidomide can be decreased when combined with Stiripentol.]
[B02BX07, lusutrombopag, The serum concentration of Pomalidomide can be increased when it is combined with Lusutrombopag.]
[J05AX24, tecovirimat, The metabolism of Pomalidomide can be increased when combined with Tecovirimat.]
[L01EM04, duvelisib, The metabolism of Pomalidomide can be decreased when combined with Duvelisib.]
[L01EB07, dacomitinib, The serum concentration of Pomalidomide can be increased when it is combined with Dacomitinib.]
[J01AA14, sarecycline, The serum concentration of Pomalidomide can be increased when it is combined with Sarecycline.]
[J01AA15, omadacycline, The serum concentration of Pomalidomide can be increased when it is combined with Omadacycline.]
[S01GX12, cetirizine, The risk or severity of adverse effects can be increased when Cetirizine is combined with Pomalidomide.]
[N05CM04, carbromal, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Carbromal.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Pomalidomide is combined with Chloroprocaine.]
[D08AE05, chloroxylenol, Pomalidomide may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[R06AA06, chlorphenoxamine, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[M01AC05, lornoxicam, Lornoxicam may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[R03DA02, oxtriphylline, The metabolism of Pomalidomide can be decreased when combined with Oxtriphylline.]
[N07XX15, inotersen, Inotersen may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[L01XK04, talazoparib, The serum concentration of Talazoparib can be increased when it is combined with Pomalidomide.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Pomalidomide.]
[R03BB08, revefenacin, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.]
[L01ED05, lorlatinib, The serum concentration of Pomalidomide can be decreased when it is combined with Lorlatinib.]
[L04AA39, emapalumab, The metabolism of Pomalidomide can be increased when combined with Emapalumab.]
[L01AD01, carmustine, The risk or severity of adverse effects can be increased when Carmustine is combined with Pomalidomide.]
[L01EX12, larotrectinib, The serum concentration of Pomalidomide can be increased when it is combined with Larotrectinib.]
[L01EX13, gilteritinib, The metabolism of Pomalidomide can be decreased when combined with Gilteritinib.]
[L01XJ03, glasdegib, The serum concentration of Pomalidomide can be increased when it is combined with Glasdegib.]
[L04AA43, ravulizumab, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Ravulizumab.]
[A06AX05, prucalopride, Prucalopride may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[B01AX07, caplacizumab, The risk or severity of bleeding can be increased when Caplacizumab is combined with Pomalidomide.]
[B01AC23, cilostazol, The metabolism of Pomalidomide can be decreased when combined with Cilostazol.]
[A03FA08, cinitapride, The risk or severity of adverse effects can be increased when Cinitapride is combined with Pomalidomide.]
[P02BX04, triclabendazole, The metabolism of Pomalidomide can be decreased when combined with Triclabendazole.]
[N06AX27, esketamine, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Esketamine.]
[L04AA42, siponimod, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Siponimod.]
[J01FA09, clarithromycin, The metabolism of Pomalidomide can be decreased when combined with Clarithromycin.]
[N06BA14, solriamfetol, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Solriamfetol.]
[N06AX29, brexanolone, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Brexanolone.]
[L01EN01, erdafitinib, The serum concentration of Pomalidomide can be increased when it is combined with Erdafitinib.]
[N05BA09, clobazam, The metabolism of Pomalidomide can be increased when combined with Clobazam.]
[H02AB14, cloprednol, The metabolism of Pomalidomide can be increased when combined with Cloprednol.]
[N05BA22, cloxazolam, The risk or severity of adverse effects can be increased when Cloxazolam is combined with Pomalidomide.]
[L04AB01, etanercept, The metabolism of Pomalidomide can be increased when combined with Etanercept.]
[H02AB17, cortivazol, The metabolism of Pomalidomide can be increased when combined with Cortivazol.]
[L04AC18, risankizumab, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Risankizumab.]
[L01EM03, alpelisib, The metabolism of Pomalidomide can be increased when combined with Alpelisib.]
[J01DC04, cefaclor, Cefaclor may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[J01DB05, cefadroxil, Cefadroxil may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[J01DC03, cefamandole, Cefamandole may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[J01DB07, cefatrizine, Cefatrizine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[J01DB04, cefazolin, Cefazolin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[L02BB06, darolutamide, The serum concentration of Pomalidomide can be increased when it is combined with Darolutamide.]
[J01DC09, cefmetazole, Cefmetazole may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[J01DC06, cefonicid, Cefonicid may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[J01DD12, cefoperazone, Cefoperazone may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[J01DD01, cefotaxime, Cefotaxime may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[J01DC05, cefotetan, Cefotetan may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N05AA06, cyamemazine, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Cyamemazine.]
[J01DC07, cefotiam, Cefotiam may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[J01DC01, cefoxitin, Cefoxitin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[J01DD03, cefsulodin, Cefsulodin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[J01DD02, ceftazidime, Ceftazidime may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[C03BX03, cicletanine, Cicletanine may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD07, ceftizoxime, Ceftizoxime may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[J01DD04, ceftriaxone, Ceftriaxone may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[S01AA27, cefuroxime, Cefuroxime may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Pomalidomide.]
[L04AA44, upadacitinib, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Upadacitinib.]
[L01EJ02, fedratinib, The serum concentration of Pomalidomide can be increased when it is combined with Fedratinib.]
[L01EX14, entrectinib, The serum concentration of Pomalidomide can be increased when it is combined with Entrectinib.]
[N07XX11, pitolisant, The serum concentration of Pomalidomide can be decreased when it is combined with Pitolisant.]
[J04AK08, pretomanid, The metabolism of Pomalidomide can be decreased when combined with Pretomanid.]
[J01XX12, lefamulin, The serum concentration of Pomalidomide can be increased when it is combined with Lefamulin.]
[N04CX01, istradefylline, The serum concentration of Pomalidomide can be increased when it is combined with Istradefylline.]
[C03AA09, cyclothiazide, Cyclothiazide may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BE04, yohimbine, The risk or severity of adverse effects can be increased when Yohimbine is combined with Pomalidomide.]
[A10AE03, insulin, regular, pork, The metabolism of Pomalidomide can be increased when combined with Insulin pork.]
[J01XX09, daptomycin, The serum concentration of Pomalidomide can be increased when it is combined with Daptomycin.]
[J01DB01, cephalexin, The metabolism of Pomalidomide can be decreased when combined with Cephalexin.]
[J01DB02, cephaloridine, Cefaloridine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[J01DB03, cephalothin, Cefalotin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[J01DB08, cephapirin, Cefapirin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[J01DB09, cephradine, The metabolism of Pomalidomide can be increased when combined with Cefradine.]
[H02AB13, deflazacort, The metabolism of Pomalidomide can be increased when combined with Deflazacort.]
[L01FD01, trastuzumab, Trastuzumab may increase the neutropenic activities of Pomalidomide.]
[L01FD03, ado-trastuzumab emtansine, The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Pomalidomide.]
[N02CC08, lasmiditan, The serum concentration of Pomalidomide can be increased when it is combined with Lasmiditan.]
[L04AX09, diroximel fumarate, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Diroximel fumarate.]
[B06AX03, voxelotor, The serum concentration of Pomalidomide can be increased when it is combined with Voxelotor.]
[N03AX25, cenobamate, The serum concentration of Pomalidomide can be decreased when it is combined with Cenobamate.]
[A16AX16, givosiran, The serum concentration of Pomalidomide can be increased when it is combined with Givosiran.]
[M09AX08, golodirsen, Pomalidomide may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[N02CD04, ubrogepant, The serum concentration of Pomalidomide can be increased when it is combined with Ubrogepant.]
[L01FX13, enfortumab vedotin, The serum concentration of Pomalidomide can be increased when it is combined with Enfortumab vedotin.]
[R06AB06, dexbrompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pomalidomide.]
[S01XA12, dexpanthenol, Pomalidomide may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[N02AX03, dezocine, The risk or severity of adverse effects can be increased when Dezocine is combined with Pomalidomide.]
[N05CM21, lemborexant, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Lemborexant.]
[L01XX72, tazemetostat, The metabolism of Pomalidomide can be decreased when combined with Tazemetostat.]
[L04AA53, teprotumumab, The risk or severity of adverse effects can be increased when Teprotumumab is combined with Pomalidomide.]
[N05AD10, lumateperone, The risk or severity of adverse effects can be increased when Lumateperone is combined with Pomalidomide.]
[M01AX21, diacetylrhein, The metabolism of Pomalidomide can be decreased when combined with Diacerein.]
[N02CD06, rimegepant, The serum concentration of Pomalidomide can be increased when it is combined with Rimegepant.]
[J05AB16, remdesivir, The metabolism of Pomalidomide can be decreased when combined with Remdesivir.]
[S01AE06, gatifloxacin, The metabolism of Pomalidomide can be decreased when combined with Gatifloxacin.]
[H02CA02, osilodrostat, The serum concentration of Pomalidomide can be increased when it is combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Pomalidomide can be decreased when combined with Amprenavir.]
[N02CC07, frovatriptan, The risk or severity of adverse effects can be increased when Frovatriptan is combined with Pomalidomide.]
[L04AA38, ozanimod, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Ozanimod.]
[N05CC04, dichloralphenazone, The risk or severity of adverse effects can be increased when Dichloralphenazone is combined with Pomalidomide.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Pomalidomide.]
[R02AA03, dichlorobenzyl alcohol, Pomalidomide may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, Pomalidomide may decrease the excretion rate of Dienogest which could result in a higher serum level.]
[A07DA04, difenoxin, The risk or severity of adverse effects can be increased when Difenoxin is combined with Pomalidomide.]
[N02AA08, dihydrocodeine, The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Pomalidomide.]
[N02CC06, eletriptan, The risk or severity of adverse effects can be increased when Eletriptan is combined with Pomalidomide.]
[M01AH02, rofecoxib, The serum concentration of Pomalidomide can be increased when it is combined with Rofecoxib.]
[L01XF03, bexarotene, The metabolism of Pomalidomide can be increased when combined with Bexarotene.]
[C08CA16, clevidipine, The metabolism of Pomalidomide can be increased when combined with Clevidipine.]
[C01BD07, dronedarone, The serum concentration of Pomalidomide can be increased when it is combined with Dronedarone.]
[N03AG02, dipropylacetamide, The risk or severity of adverse effects can be increased when Valpromide is combined with Pomalidomide.]
[J01FA13, dirithromycin, The metabolism of Pomalidomide can be decreased when combined with Dirithromycin.]
[L01AA02, chlorambucil, The risk or severity of adverse effects can be increased when Chlorambucil is combined with Pomalidomide.]
[S03AA08, chloramphenicol, The metabolism of Pomalidomide can be decreased when combined with Chloramphenicol.]
[N05BA02, chlordiazepoxide, The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Pomalidomide.]
[L01EH03, tucatinib, Tucatinib may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[A03AA08, dihexyverine, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[L01EX17, capmatinib, The serum concentration of Pomalidomide can be increased when it is combined with Capmatinib.]
[D07XB03, fluprednidene, The metabolism of Pomalidomide can be increased when combined with Fluprednidene.]
[G04BD09, trospium, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[M01AC04, droxicam, Droxicam may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[L01EX19, ripretinib, The serum concentration of Pomalidomide can be increased when it is combined with Ripretinib.]
[V08CA05, mangafodipir, Mangafodipir may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[B01AE02, lepirudin, The risk or severity of bleeding can be increased when Lepirudin is combined with Pomalidomide.]
[M02AA27, dexketoprofen, Dexketoprofen may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N05CM02, chlormethiazole, The risk or severity of adverse effects can be increased when Clomethiazole is combined with Pomalidomide.]
[M03BB02, chlormezanone, The risk or severity of adverse effects can be increased when Chlormezanone is combined with Pomalidomide.]
[L04AA47, inebilizumab, The risk or severity of infection can be increased when Pomalidomide is combined with Inebilizumab.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Pomalidomide is combined with Dyclonine.]
[R05CB11, stepronin, The risk or severity of adverse effects can be increased when Stepronin is combined with Pomalidomide.]
[R06AX22, ebastine, The metabolism of Pomalidomide can be decreased when combined with Ebastine.]
[J05AX29, fostemsavir, The serum concentration of Pomalidomide can be increased when it is combined with Fostemsavir.]
[N05CD14, remimazolam, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Remimazolam.]
[N07XX04, sodium oxybate, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[L01FX15, belantamab mafodotin, The serum concentration of Pomalidomide can be increased when it is combined with Belantamab mafodotin.]
[L04AC19, satralizumab, The serum concentration of Pomalidomide can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Pomalidomide is combined with Oliceridine.]
[P01BA01, chloroquine, Chloroquine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[L01EX23, pralsetinib, The serum concentration of Pomalidomide can be increased when it is combined with Pralsetinib.]
[C03AA04, chlorothiazide, Chlorothiazide may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AB04, chlorpheniramine, The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Pomalidomide.]
[N05AA01, chlorpromazine, The metabolism of Pomalidomide can be increased when combined with Chlorpromazine.]
[A10BB02, chlorpropamide, Chlorpropamide may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N05AF03, chlorprothixene, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.]
[C03BA04, chlorthalidone, Chlorthalidone may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[M03BB03, chlorzoxazone, The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Pomalidomide.]
[N05BX03, etifoxine, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Etifoxine.]
[N02BA07, ethenzamide, Ethenzamide may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N02BA03, choline salicylate, Pomalidomide may decrease the excretion rate of Choline salicylate which could result in a higher serum level.]
[N06BX18, vinpocetine, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Vinpocetine.]
[N05BA18, ethyl loflazepate, The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Pomalidomide.]
[M01AB08, etodolac, Etodolac may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[M02AA06, etofenamate, Etofenamate may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[B06AC06, berotralstat, The serum concentration of Pomalidomide can be increased when it is combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Pomalidomide can be decreased when combined with Lonafarnib.]
[L01BB05, fludarabine, The risk or severity of adverse effects can be increased when Fludarabine is combined with Pomalidomide.]
[L02BX04, relugolix, The serum concentration of Pomalidomide can be increased when it is combined with Relugolix.]
[M01AX25, chondroitin sulfates, Pomalidomide may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[L04AD03, voclosporin, The serum concentration of Pomalidomide can be increased when it is combined with Voclosporin.]
[P03AX07, abametapir, The serum concentration of Pomalidomide can be increased when it is combined with Abametapir.]
[L01EX21, tepotinib, The serum concentration of Pomalidomide can be increased when it is combined with Tepotinib.]
[L01EX25, umbralisib, The serum concentration of Pomalidomide can be increased when it is combined with Umbralisib.]
[V03AF12, trilaciclib, The metabolism of Pomalidomide can be increased when combined with Trilaciclib.]
[M03BA05, febarbamate, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Febarbamate.]
[N03AX10, felbamate, The metabolism of Pomalidomide can be increased when combined with Felbamate.]
[M01AE05, fenbufen, Fenbufen may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N06BA10, fenethylline, The metabolism of Pomalidomide can be decreased when combined with Fenethylline.]
[C01CA19, fenoldopam, Fenoldopam may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[J01DD15, cefdinir, Cefdinir may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[J01MB07, flumequine, The metabolism of Pomalidomide can be decreased when combined with Flumequine.]
[R03BA03, flunisolide, The metabolism of Pomalidomide can be increased when combined with Flunisolide.]
[S02BA08, fluocinolone acetonide, The metabolism of Pomalidomide can be increased when combined with Fluocinolone acetonide.]
[N02BG07, flupirtine, Flupirtine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[L04AA50, ponesimod, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Ponesimod.]
[L01EK03, tivozanib, The serum concentration of Pomalidomide can be increased when it is combined with Tivozanib.]
[N01AB05, trichloroethylene, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Trichloroethylene.]
[L03AB10, peginterferon alfa-2b, The serum concentration of Pomalidomide can be increased when it is combined with Peginterferon alfa-2b.]
[L01FX22, loncastuximab tesirine, The serum concentration of Pomalidomide can be increased when it is combined with Loncastuximab tesirine.]
[A02BA01, cimetidine, The metabolism of Pomalidomide can be decreased when combined with Cimetidine.]
[N02BF01, gabapentin, The risk or severity of adverse effects can be increased when Gabapentin is combined with Pomalidomide.]
[V08CA04, gadoteridol, Gadoteridol may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N07CA02, cinnarizine, The metabolism of Pomalidomide can be decreased when combined with Cinnarizine.]
[J01MB06, cinoxacin, The metabolism of Pomalidomide can be decreased when combined with Cinoxacin.]
[L01XX73, sotorasib, The serum concentration of Pomalidomide can be decreased when it is combined with Sotorasib.]
[L01EN03, infigratinib, The metabolism of Pomalidomide can be decreased when combined with Infigratinib.]
[S03AA07, ciprofloxacin, The serum concentration of Pomalidomide can be increased when it is combined with Ciprofloxacin.]
[L01XA01, cisplatin, The risk or severity of adverse effects can be increased when Cisplatin is combined with Pomalidomide.]
[N06AB04, citalopram, The metabolism of Pomalidomide can be decreased when combined with Citalopram.]
[L04AA54, pegcetacoplan, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Pegcetacoplan.]
[H01AC07, somapacitan, The metabolism of Pomalidomide can be increased when combined with Somapacitan.]
[C03DA05, finerenone, Finerenone may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AA48, belumosudil, The serum concentration of Pomalidomide can be increased when it is combined with Belumosudil.]
[P01CA03, fexinidazole, The metabolism of Pomalidomide can be decreased when combined with Fexinidazole.]
[L04AA51, anifrolumab, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Anifrolumab.]
[L01XX74, belzutifan, The serum concentration of Pomalidomide can be decreased when it is combined with Belzutifan.]
[H01AC09, lonapegsomatropin, The metabolism of Pomalidomide can be increased when combined with Lonapegsomatropin.]
[L01EB10, mobocertinib, The serum concentration of Pomalidomide can be decreased when it is combined with Mobocertinib.]
[V09AB03, ioflupane I-123, Ioflupane I-123 may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[V09AA01, technetium Tc 99m exametazime, Pomalidomide may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09GA01, technetium Tc 99m sestamibi, The serum concentration of Pomalidomide can be increased when it is combined with Technetium Tc-99m sestamibi.]
[V09AX06, florbetaben f-18, Pomalidomide may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[L04AA59, avacopan, The metabolism of Pomalidomide can be decreased when combined with Avacopan.]
[R06AA04, clemastine, The risk or severity of adverse effects can be increased when Clemastine is combined with Pomalidomide.]
[M01AG01, mefenamic acid, The metabolism of Pomalidomide can be decreased when combined with Mefenamic acid.]
[N06AX25, St. John's wort extract, The serum concentration of Pomalidomide can be decreased when it is combined with St. John's Wort.]
[L01EA06, asciminib, The serum concentration of Pomalidomide can be increased when it is combined with Asciminib.]
[J05AX10, maribavir, The serum concentration of Pomalidomide can be increased when it is combined with Maribavir.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Pomalidomide.]
[D11AH08, abrocitinib, The serum concentration of Pomalidomide can be increased when it is combined with Abrocitinib.]
[J04BA01, clofazimine, The serum concentration of Pomalidomide can be increased when it is combined with Clofazimine.]
[B01AD11, tenecteplase, The risk or severity of bleeding can be increased when Tenecteplase is combined with Pomalidomide.]
[C10AB01, clofibrate, The metabolism of Pomalidomide can be increased when combined with Clofibrate.]
[B06AX04, mitapivat, The metabolism of Pomalidomide can be increased when combined with Mitapivat.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Pomalidomide is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The serum concentration of Pomalidomide can be increased when it is combined with Pacritinib.]
[G03GB02, clomiphene, The serum concentration of Pomalidomide can be increased when it is combined with Clomifene.]
[N06AA04, clomipramine, The metabolism of Pomalidomide can be decreased when combined with Clomipramine.]
[N03AE01, clonazepam, The risk or severity of adverse effects can be increased when Clonazepam is combined with Pomalidomide.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Pomalidomide.]
[C01EB24, mavacamten, The serum concentration of Pomalidomide can be decreased when it is combined with Mavacamten.]
[J05AH02, oseltamivir, Oseltamivir may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[C03BA03, clopamide, Clopamide may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AC22, spesolimab, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Spesolimab.]
[L04AA56, deucravacitinib, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Deucravacitinib.]
[N05AH06, clothiapine, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Clothiapine.]
[N05BA21, clotiazepam, The risk or severity of adverse effects can be increased when Clotiazepam is combined with Pomalidomide.]
[A04AA01, ondansetron, The risk or severity of adverse effects can be increased when Ondansetron is combined with Pomalidomide.]
[A04AA02, granisetron, The risk or severity of adverse effects can be increased when Granisetron is combined with Pomalidomide.]
[J05AX31, lenacapavir, The metabolism of Pomalidomide can be decreased when combined with Lenacapavir.]
[N05AH02, clozapine, The risk or severity of neutropenia can be increased when Pomalidomide is combined with Clozapine.]
[L01EN04, futibatinib, The serum concentration of Pomalidomide can be increased when it is combined with Futibatinib.]
[A10BK06, sotagliflozin, The serum concentration of Pomalidomide can be increased when it is combined with Sotagliflozin.]
[J01GB12, arbekacin, Pomalidomide may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[N05BA13, halazepam, The risk or severity of adverse effects can be increased when Halazepam is combined with Pomalidomide.]
[H01AC08, somatrogon, The metabolism of Pomalidomide can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Pomalidomide is combined with Cocaine.]
[C02KB01, metyrosine, Pomalidomide may increase the sedative activities of Metyrosine.]
[L04AC21, bimekizumab, The metabolism of Pomalidomide can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, Proquazone may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Codeine is combined with Pomalidomide.]
[M03AC05, hexafluorenium, The risk or severity of adverse effects can be increased when Hexafluronium is combined with Pomalidomide.]
[M04AC01, colchicine, The serum concentration of Pomalidomide can be increased when it is combined with Colchicine.]
[A03AB10, hexocyclium, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[A03BB06, homatropine methylbromide, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[J01XB01, colistin, Pomalidomide may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, Cefpirome may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[L04AA13, leflunomide, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Leflunomide.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Desflurane is combined with Pomalidomide.]
[A04AA03, tropisetron, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Tropisetron.]
[C04AX28, ifenprodil, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Ifenprodil.]
[A10BX03, nateglinide, Nateglinide may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N02BA16, imidazole-2-hydroxybenzoate, Imidazole salicylate may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[L01BB07, nelarabine, The risk or severity of adverse effects can be increased when Nelarabine is combined with Pomalidomide.]
[J01FA15, telithromycin, The metabolism of Pomalidomide can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, The risk or severity of adverse effects can be increased when Ciclesonide is combined with Pomalidomide.]
[B01AC10, indobufen, The risk or severity of bleeding can be increased when Indobufen is combined with Pomalidomide.]
[R06AX27, desloratadine, The risk or severity of adverse effects can be increased when Desloratadine is combined with Pomalidomide.]
[J05AB14, valganciclovir, Valganciclovir may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[C05BB03, invert sugar, Pomalidomide may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Iodixanol may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[V08AB05, iopromide, Pomalidomide may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Pomalidomide may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Pomalidomide may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, Valdecoxib may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N02CC05, almotriptan, The risk or severity of adverse effects can be increased when Almotriptan is combined with Pomalidomide.]
[M01AH04, parecoxib, Parecoxib may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[J02AC02, itraconazole, The metabolism of Pomalidomide can be decreased when combined with Itraconazole.]
[B01AB12, bemiparin, The risk or severity of bleeding can be increased when Bemiparin is combined with Pomalidomide.]
[S01AD03, acyclovir, The metabolism of Pomalidomide can be decreased when combined with Acyclovir.]
[N05BA10, ketazolam, The metabolism of Pomalidomide can be decreased when combined with Ketazolam.]
[M01AA06, kebuzone, Kebuzone may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[L01EA01, imatinib, The serum concentration of Pomalidomide can be increased when it is combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Pomalidomide can be decreased when combined with Posaconazole.]
[B03XA02, darbepoetin alfa, The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Pomalidomide.]
[N03AX09, lamotrigine, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.]
[S01BA03, cortisone, The metabolism of Pomalidomide can be increased when combined with Cortisone.]
[N07BC04, lofexidine, The therapeutic efficacy of Pomalidomide can be increased when used in combination with Lofexidine.]
[S01AE04, lomefloxacin, The metabolism of Pomalidomide can be decreased when combined with Lomefloxacin.]
[M01AB09, lonazolac, Lonazolac may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N05CD06, lormetazepam, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Lormetazepam.]
[M02AA31, loxoprofen, Loxoprofen may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[J01DC08, loracarbef, Loracarbef may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[C09AA03, lisinopril, Lisinopril may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[A06AD01, magnesium carbonate, Pomalidomide may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.]
[C08CA11, manidipine, The metabolism of Pomalidomide can be decreased when combined with Manidipine.]
[A03AA04, mebeverine, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Medifoxamine.]
[H02AB15, meprednisone, The metabolism of Pomalidomide can be increased when combined with Meprednisone.]
[R06AD07, mequitazine, The metabolism of Pomalidomide can be decreased when combined with Mequitazine.]
[J01DH02, meropenem, Meropenem may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N04AA03, methixene, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Metixene.]
[R06AE03, cyclizine, The risk or severity of adverse effects can be increased when Cyclizine is combined with Pomalidomide.]
[N05CA10, cyclobarbital, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Cyclobarbital.]
[C03DA04, eplerenone, Eplerenone may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AD03, metylperon, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Melperone.]
[L04AA15, alefacept, The risk or severity of adverse effects can be increased when Alefacept is combined with Pomalidomide.]
[C03AA07, cyclopenthiazide, Cyclopenthiazide may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[J01FA03, midecamycin, The metabolism of Pomalidomide can be decreased when combined with Midecamycin.]
[J05AF07, tenofovir disoproxil, The serum concentration of Pomalidomide can be increased when it is combined with Tenofovir disoproxil.]
[L01AA01, cyclophosphamide, The metabolism of Pomalidomide can be increased when combined with Cyclophosphamide.]
[N06AX07, minaprine, The risk or severity of adverse effects can be increased when Minaprine is combined with Pomalidomide.]
[S01XA18, cyclosporine, Pomalidomide may increase the immunosuppressive activities of Cyclosporine.]
[N06AG02, moclobemide, The risk or severity of adverse effects can be increased when Moclobemide is combined with Pomalidomide.]
[N06BA07, modafinil, The metabolism of Pomalidomide can be increased when combined with Modafinil.]
[R06AX02, cyproheptadine, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.]
[C10AA07, rosuvastatin, The metabolism of Pomalidomide can be decreased when combined with Rosuvastatin.]
[M02AA02, mofebutazone, Mofebutazone may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[M01AX22, morniflumate, Morniflumate may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[C03XA02, conivaptan, The metabolism of Pomalidomide can be decreased when combined with Conivaptan.]
[L01BC01, cytarabine, The risk or severity of adverse effects can be increased when Cytarabine is combined with Pomalidomide.]
[J05AF10, entecavir, The metabolism of Pomalidomide can be decreased when combined with Entecavir.]
[G04BE09, vardenafil, The serum concentration of Pomalidomide can be increased when it is combined with Vardenafil.]
[M01AH05, etoricoxib, The metabolism of Pomalidomide can be decreased when combined with Etoricoxib.]
[L01AX04, dacarbazine, The risk or severity of adverse effects can be increased when Dacarbazine is combined with Pomalidomide.]
[L01DA01, dactinomycin, The risk or severity of adverse effects can be increased when Dactinomycin is combined with Pomalidomide.]
[G03XA01, danazol, The metabolism of Pomalidomide can be decreased when combined with Danazol.]
[M03CA01, dantrolene, The risk or severity of adverse effects can be increased when Dantrolene is combined with Pomalidomide.]
[L01DB02, daunorubicin, The metabolism of Pomalidomide can be decreased when combined with Daunorubicin.]
[N06BX04, deanol, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Deanol.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.]
[M01AX01, nabumetone, The metabolism of Pomalidomide can be decreased when combined with Nabumetone.]
[N07BB05, nalmefene, Nalmefene may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N05BA16, nordazepam, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Nordazepam.]
[S01GX04, nedocromil, Nedocromil may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N06AX06, nefazodone, The metabolism of Pomalidomide can be decreased when combined with Nefazodone.]
[N05CM16, niaprazine, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Niaprazine.]
[C01DX16, nicorandil, Pomalidomide may decrease the excretion rate of Nicorandil which could result in a higher serum level.]
[L02BB02, nilutamide, Nilutamide may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N03AG06, tiagabine, The risk or severity of adverse effects can be increased when Tiagabine is combined with Pomalidomide.]
[C01CA23, theodrenaline, The metabolism of Theodrenaline can be decreased when combined with Pomalidomide.]
[M03AC11, cisatracurium, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Pomalidomide.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Normethadone.]
[B01AX05, fondaparinux, Fondaparinux may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[D11AH02, pimecrolimus, The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pomalidomide.]
[N06AB10, escitalopram, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Escitalopram.]
[G04BD08, solifenacin, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.]
[A07EC03, olsalazine, Olsalazine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N06AA01, desipramine, The metabolism of Pomalidomide can be decreased when combined with Desipramine.]
[H01BA02, desmopressin, Desmopressin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[D07XC02, desoximetasone, The risk or severity of adverse effects can be increased when Desoximetasone is combined with Pomalidomide.]
[V04CH02, indigo carmine, Pomalidomide may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[J01DH03, ertapenem, Ertapenem may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[L01XA03, oxaliplatin, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Pomalidomide.]
[M01AE12, oxaprozin, Oxaprozin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N03AF02, oxcarbazepine, The metabolism of Pomalidomide can be increased when combined with Oxcarbazepine.]
[S03BA01, dexamethasone, The metabolism of Pomalidomide can be increased when combined with Dexamethasone.]
[N06BX07, oxiracetam, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Oxiracetam.]
[N04AA08, dexetimide, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.]
[G04BD04, oxybutynin, The metabolism of Pomalidomide can be decreased when combined with Oxybutynin.]
[A08AA04, dexfenfluramine, The metabolism of Pomalidomide can be decreased when combined with Dexfenfluramine.]
[A03AA01, oxyphencyclimine, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[L04AB04, adalimumab, The metabolism of Pomalidomide can be increased when combined with Adalimumab.]
[N06BA02, dextroamphetamine, Amphetamine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[R05DA09, dextromethorphan, The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Pomalidomide.]
[N03AC01, paramethadione, The risk or severity of adverse effects can be increased when Paramethadione is combined with Pomalidomide.]
[N02AC01, dextromoramide, The risk or severity of adverse effects can be increased when Dextromoramide is combined with Pomalidomide.]
[N06AB05, paroxetine, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Paroxetine.]
[B01AC04, clopidogrel, The metabolism of Pomalidomide can be decreased when combined with Clopidogrel.]
[N07BC06, heroin, The risk or severity of adverse effects can be increased when Diamorphine is combined with Pomalidomide.]
[C01DA05, pentaerythritol tetranitrate, Pentaerythritol tetranitrate may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[C04AD01, pentifylline, The metabolism of Pentifylline can be decreased when combined with Pomalidomide.]
[P03AC04, permethrin, Permethrin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N05BA01, diazepam, The risk or severity of adverse effects can be increased when Diazepam is combined with Pomalidomide.]
[N03AX07, phenacemide, The risk or severity of adverse effects can be increased when Phenacemide is combined with Pomalidomide.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Pomalidomide is combined with Phenol.]
[N03AD02, phensuximide, The risk or severity of adverse effects can be increased when Phensuximide is combined with Pomalidomide.]
[N06AA08, dibenzepin, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Dibenzepin.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Pomalidomide is combined with Cinchocaine.]
[R05DA08, pholcodine, Pomalidomide may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[M05BA02, clodronic acid, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Pomalidomide is combined with Clodronic acid.]
[S01EC02, dichlorphenamide, Diclofenamide may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC03, diclofenac, The metabolism of Pomalidomide can be decreased when combined with Diclofenac.]
[J01CF01, dicloxacillin, The metabolism of Pomalidomide can be increased when combined with Dicloxacillin.]
[J05AD01, foscarnet, Foscarnet may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[A03AA07, dicyclomine, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[J05AF02, didanosine, Didanosine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Pipamperone.]
[A03AB14, pipenzolate, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[L01DC04, ixabepilone, The serum concentration of Pomalidomide can be increased when it is combined with Ixabepilone.]
[L01EB02, erlotinib, The metabolism of Pomalidomide can be decreased when combined with Erlotinib.]
[L01DB08, pirarubicin, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Pirarubicin.]
[C03CA03, piretanide, Piretanide may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[A08AA03, diethylpropion, The risk or severity of adverse effects can be increased when Diethylpropion is combined with Pomalidomide.]
[L02AA01, diethylstilbestrol, The metabolism of Pomalidomide can be decreased when combined with Diethylstilbestrol.]
[C08CA03, isradipine, The metabolism of Pomalidomide can be decreased when combined with Isradipine.]
[D07XC04, diflucortolone, The metabolism of Pomalidomide can be increased when combined with Difluocortolone.]
[A03AB11, poldine, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[N02BA11, diflunisal, Diflunisal may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[C01AA04, digitoxin, The serum concentration of Pomalidomide can be increased when it is combined with Digitoxin.]
[C01AA05, digoxin, Pomalidomide may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C02DB01, dihydralazine, The metabolism of Pomalidomide can be decreased when combined with Dihydralazine.]
[L01XX24, pegaspargase, The risk or severity of adverse effects can be increased when Pegaspargase is combined with Pomalidomide.]
[C04AE04, dihydroergocristine, The metabolism of Pomalidomide can be decreased when combined with Dihydroergocristine.]
[N02CA01, dihydroergotamine, The metabolism of Pomalidomide can be decreased when combined with Dihydroergotamine.]
[N02AA03, hydromorphone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Pomalidomide.]
[L04AX04, lenalidomide, The risk or severity of adverse effects can be increased when Lenalidomide is combined with Pomalidomide.]
[J05AE08, atazanavir, The metabolism of Pomalidomide can be decreased when combined with Atazanavir.]
[H03BC01, potassium perchlorate, Pomalidomide may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.]
[V03AB04, pralidoxime, Pralidoxime may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Pomalidomide is combined with Pramocaine.]
[C08DB01, diltiazem, The metabolism of Pomalidomide can be decreased when combined with Diltiazem.]
[R06AA11, dimenhydrinate, The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Pomalidomide.]
[V03AB09, dimercaprol, Dimercaprol may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[M03BX03, pridinol, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Pridinol.]
[R06AB03, dimethindene, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[M02AX03, dimethyl sulfoxide, The metabolism of Pomalidomide can be decreased when combined with Dimethyl sulfoxide.]
[N03AG05, progabide, The risk or severity of adverse effects can be increased when Progabide is combined with Pomalidomide.]
[N06BC02, propentofylline, The metabolism of Pomalidomide can be decreased when combined with Propentofylline.]
[N02BB04, propyphenazone, Propyphenazone may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[M01AB14, proglumetacin, Proglumetacin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[C05CA03, diosmin, The serum concentration of Pomalidomide can be increased when it is combined with Diosmin.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Pomalidomide is combined with Proparacaine.]
[R03DA03, proxyphylline, The metabolism of Proxyphylline can be decreased when combined with Pomalidomide.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Pomalidomide is combined with Diphenhydramine.]
[A07DA01, diphenoxylate, The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Pomalidomide.]
[N05CD10, quazepam, The risk or severity of adverse effects can be increased when Quazepam is combined with Pomalidomide.]
[B01AC07, dipyridamole, The risk or severity of bleeding can be increased when Dipyridamole is combined with Pomalidomide.]
[N06BA11, dexmethylphenidate, The risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Pomalidomide.]
[B01AD10, drotrecogin alfa, The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Pomalidomide.]
[N06AA23, quinupramine, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Quinupramine.]
[A03FA02, cisapride, The metabolism of Pomalidomide can be decreased when combined with Cisapride.]
[S01XA23, sirolimus, The risk or severity of adverse effects can be increased when Sirolimus is combined with Pomalidomide.]
[N05AL04, remoxipride, The risk or severity of adverse effects can be increased when Remoxipride is combined with Pomalidomide.]
[S01AX06, resorcinol, Pomalidomide may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[L04AA23, natalizumab, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Natalizumab.]
[S02AA12, rifamycin SV, The serum concentration of Pomalidomide can be increased when it is combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Pomalidomide can be increased when combined with Rifapentine.]
[N07XX02, riluzole, The risk or severity of adverse effects can be increased when Riluzole is combined with Pomalidomide.]
[N05AX08, risperidone, The risk or severity of adverse effects can be increased when Risperidone is combined with Pomalidomide.]
[R06AE09, levocetirizine, The risk or severity of adverse effects can be increased when Levocetirizine is combined with Pomalidomide.]
[L04AA21, efalizumab, The risk or severity of adverse effects can be increased when Efalizumab is combined with Pomalidomide.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Pomalidomide is combined with Ropivacaine.]
[J01MB01, rosoxacin, The metabolism of Pomalidomide can be decreased when combined with Rosoxacin.]
[L01EX01, sunitinib, The risk or severity of adverse effects can be increased when Sunitinib is combined with Pomalidomide.]
[A04AD12, aprepitant, The metabolism of Pomalidomide can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, Tolvaptan may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XG01, bortezomib, The risk or severity of adverse effects can be increased when Bortezomib is combined with Pomalidomide.]
[J05AE07, fosamprenavir, The metabolism of Pomalidomide can be decreased when combined with Fosamprenavir.]
[G04BE08, tadalafil, Tadalafil may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[S01BC05, ketorolac, Ketorolac may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[C02KX02, ambrisentan, The serum concentration of Pomalidomide can be increased when it is combined with Ambrisentan.]
[C01EB18, ranolazine, The serum concentration of Pomalidomide can be increased when it is combined with Ranolazine.]
[N02BA06, salsalate, Salsalate may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[H05BA01, salmon calcitonin, Salmon calcitonin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[C01CA07, dobutamine, Dobutamine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[A03FA03, domperidone, The metabolism of Pomalidomide can be decreased when combined with Domperidone.]
[C01CA04, dopamine, Dopamine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N06AA16, dothiepin, The metabolism of Pomalidomide can be decreased when combined with Dosulepin.]
[N06AA12, doxepin, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[L01DB01, doxorubicin, The metabolism of Pomalidomide can be decreased when combined with Doxorubicin.]
[J01AA02, doxycycline, Doxycycline may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.]
[N06AB06, sertraline, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of adverse effects can be increased when Sevoflurane is combined with Pomalidomide.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.]
[A08AA10, sibutramine, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Sibutramine.]
[C10AA01, simvastatin, The serum concentration of Pomalidomide can be increased when it is combined with Simvastatin.]
[A12CA02, sodium sulfate, Pomalidomide may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.]
[R03DA01, dyphylline, Dyphylline may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N05AL02, sultopride, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Sultopride.]
[N02CC01, sumatriptan, The risk or severity of adverse effects can be increased when Sumatriptan is combined with Pomalidomide.]
[V04CX07, edrophonium, Edrophonium may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[C07AB13, talinolol, The serum concentration of Pomalidomide can be increased when it is combined with Talinolol.]
[H01AA01, corticotropin, The metabolism of Pomalidomide can be increased when combined with Corticotropin.]
[J01MA05, temafloxacin, The metabolism of Pomalidomide can be decreased when combined with Temafloxacin.]
[L01AX03, temozolomide, The risk or severity of adverse effects can be increased when Temozolomide is combined with Pomalidomide.]
[M01AC02, tenoxicam, Tenoxicam may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[D01BA02, terbinafine, The metabolism of Pomalidomide can be increased when combined with Terbinafine.]
[M03BX07, tetrazepam, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Tetrazepam.]
[M03BX05, thiocolchicoside, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Thiocolchicoside.]
[N05AB05, thiopropazate, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Thiopropazate.]
[G04BD01, emepronium, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Emepronium.]
[N06AX14, tianeptine, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Tianeptine.]
[N05BA23, tofisopam, The risk or severity of adverse effects can be increased when Tofisopam is combined with Pomalidomide.]
[M01AG02, tolfenamic acid, Tolfenamic acid may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N06AG03, toloxatone, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Toloxatone.]
[N06BA09, atomoxetine, Atomoxetine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N03AX11, topiramate, The metabolism of Pomalidomide can be increased when combined with Topiramate.]
[L02BA02, toremifene, The serum concentration of Pomalidomide can be increased when it is combined with Toremifene.]
[C03CA04, torsemide, Torasemide may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD11, triazulenone, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Loprazolam.]
[N05CC01, chloral hydrate, The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Pomalidomide.]
[N05CM07, triclofos, The risk or severity of adverse effects can be increased when Triclofos is combined with Pomalidomide.]
[A03AB08, tridihexethyl, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[B01AC18, triflusal, The risk or severity of bleeding can be increased when Triflusal is combined with Pomalidomide.]
[H02CA01, trilostane, The risk or severity of adverse effects can be increased when Trilostane is combined with Pomalidomide.]
[R06AA10, trimethobenzamide, The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Pomalidomide.]
[L01AA07, trofosfamide, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Trofosfamide.]
[N04AA12, tropatepine, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.]
[C05CA04, troxerutin, The risk or severity of bleeding can be increased when Troxerutin is combined with Pomalidomide.]
[N01AB04, enflurane, The risk or severity of adverse effects can be increased when Enflurane is combined with Pomalidomide.]
[C02CA06, urapidil, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Urapidil.]
[J01MA04, enoxacin, The serum concentration of Pomalidomide can be increased when it is combined with Enoxacin.]
[N05AL06, veralipride, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Veralipride.]
[L01CA04, vinorelbine, The risk or severity of adverse effects can be increased when Vinorelbine is combined with Pomalidomide.]
[S01GX10, epinastine, The risk or severity of adverse effects can be increased when Epinastine is combined with Pomalidomide.]
[N06AX16, venlafaxine, The risk or severity of adverse effects can be increased when Venlafaxine is combined with Pomalidomide.]
[C08CA12, mepirodipine, The metabolism of Pomalidomide can be decreased when combined with Barnidipine.]
[S01EA01, epinephrine, The metabolism of Pomalidomide can be decreased when combined with Epinephrine.]
[L01DB03, epirubicin, The risk or severity of adverse effects can be increased when Epirubicin is combined with Pomalidomide.]
[N05CF02, zolpidem, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[M01AB04, zomepirac, Zomepirac may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N03AX15, zonisamide, The serum concentration of Pomalidomide can be increased when it is combined with Zonisamide.]
[N05CF01, zopiclone, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Zopiclone.]
[N05AX11, zotepine, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Zotepine.]
[B01AD03, anistreplase, The risk or severity of bleeding can be increased when Anistreplase is combined with Pomalidomide.]
[L01XA02, carboplatin, The risk or severity of adverse effects can be increased when Carboplatin is combined with Pomalidomide.]
[C02AC02, guanfacine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Pomalidomide.]
[B01AC11, iloprost, The risk or severity of bleeding can be increased when Iloprost is combined with Pomalidomide.]
[C01BG01, moricizine, The risk or severity of adverse effects can be increased when Moricizine is combined with Pomalidomide.]
[G02AB03, ergonovine, The risk or severity of adverse effects can be increased when Ergometrine is combined with Pomalidomide.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Pomalidomide.]
[N02CA02, ergotamine, The metabolism of Pomalidomide can be decreased when combined with Ergotamine.]
[L03AX05, pidotimod, Pomalidomide may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[S01AA17, erythromycin, The serum concentration of Pomalidomide can be increased when it is combined with Erythromycin.]
[N05CD04, estazolam, The risk or severity of adverse effects can be increased when Estazolam is combined with Pomalidomide.]
[A02BC02, pantoprazole, Pantoprazole may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[H05BX01, cinacalcet, The metabolism of Pomalidomide can be decreased when combined with Cinacalcet.]
[G03CA03, estradiol, The metabolism of Pomalidomide can be decreased when combined with Estradiol.]
[L01XX11, estramustine, The risk or severity of adverse effects can be increased when Estramustine is combined with Pomalidomide.]
[G03CA57, estrogens, conjugated (USP), The metabolism of Pomalidomide can be decreased when combined with Conjugated estrogens.]
[J04AK02, ethambutol, The metabolism of Pomalidomide can be decreased when combined with Ethambutol.]
[R03BA09, fluticasone furoate, The metabolism of Pomalidomide can be increased when combined with Fluticasone furoate.]
[R03BA05, fluticasone, The metabolism of Pomalidomide can be increased when combined with Fluticasone.]
[V08CA03, gadodiamide, Gadodiamide may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N05CM08, ethchlorvynol, The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pomalidomide.]
[L02AA03, ethinyl estradiol, The metabolism of Pomalidomide can be decreased when combined with Ethinylestradiol.]
[C01BD05, ibutilide, Ibutilide may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N04AA05, profenamine, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Profenamine.]
[N03AD01, ethosuximide, The risk or severity of adverse effects can be increased when Ethosuximide is combined with Pomalidomide.]
[N03AB01, ethotoin, The risk or severity of adverse effects can be increased when Ethotoin is combined with Pomalidomide.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Pomalidomide is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Pomalidomide is combined with Meloxicam.]
[S01XA06, ethylmorphine, The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Pomalidomide.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Pomalidomide is combined with Etidocaine.]
[N01AX07, etomidate, The risk or severity of adverse effects can be increased when Etomidate is combined with Pomalidomide.]
[L01CB01, etoposide, The risk or severity of adverse effects can be increased when Etoposide is combined with Pomalidomide.]
[N05AE03, sertindole, The risk or severity of adverse effects can be increased when Sertindole is combined with Pomalidomide.]
[L04AD02, tacrolimus, Tacrolimus may increase the immunosuppressive activities of Pomalidomide.]
[R06AX11, astemizole, The metabolism of Pomalidomide can be decreased when combined with Astemizole.]
[R06AX12, terfenadine, The metabolism of Pomalidomide can be decreased when combined with Terfenadine.]
[P01AX07, trimetrexate, Trimetrexate may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N06AX12, bupropion, The risk or severity of adverse effects can be increased when Bupropion is combined with Pomalidomide.]
[N06AB08, fluvoxamine, The serum concentration of Pomalidomide can be increased when it is combined with Fluvoxamine.]
[C01BB03, tocainide, The metabolism of Pomalidomide can be decreased when combined with Tocainide.]
[L02AE02, leuprolide, Leuprolide may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[L04AA02, muromonab-CD3, The risk or severity of adverse effects can be increased when Muromonab is combined with Pomalidomide.]
[C10AA03, pravastatin, The serum concentration of Pomalidomide can be increased when it is combined with Pravastatin.]
[M01CB01, gold sodium thiomalate, Pomalidomide may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[B05AA05, dextran, Pomalidomide may decrease the excretion rate of Dextran which could result in a higher serum level.]
[V03AF02, dexrazoxane, The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Pomalidomide.]
[A02BA03, famotidine, The metabolism of Pomalidomide can be decreased when combined with Famotidine.]
[A16AA01, levocarnitine, Levocarnitine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[P02CA03, albendazole, The metabolism of Pomalidomide can be increased when combined with Albendazole.]
[N03AX26, fenfluramine, The risk or severity of adverse effects can be increased when Fenfluramine is combined with Pomalidomide.]
[M01AE04, fenoprofen, Fenoprofen may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N02AB03, fentanyl, The risk or severity of adverse effects can be increased when Fentanyl is combined with Pomalidomide.]
[R03CC02, albuterol, Salbutamol may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[B01AD05, plasmin, The risk or severity of bleeding can be increased when Fibrinolysin is combined with Pomalidomide.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Clofarabine is combined with Pomalidomide.]
[L04AA40, cladribine, The risk or severity of adverse effects can be increased when Cladribine is combined with Pomalidomide.]
[N07AX03, cevimeline, Cevimeline may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[G04BD02, flavoxate, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[C01BC04, flecainide, The metabolism of Pomalidomide can be decreased when combined with Flecainide.]
[N02BG04, floctafenine, Floctafenine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[J01CF05, floxacillin, The metabolism of Pomalidomide can be increased when combined with Flucloxacillin.]
[J02AC01, fluconazole, The serum concentration of Pomalidomide can be increased when it is combined with Fluconazole.]
[J02AX01, flucytosine, The risk or severity of adverse effects can be increased when Flucytosine is combined with Pomalidomide.]
[H02AA02, fludrocortisone, The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Pomalidomide.]
[V03AB25, flumazenil, Flumazenil may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N07CA03, flunarizine, The risk or severity of adverse effects can be increased when Flunarizine is combined with Pomalidomide.]
[N05CD03, flunitrazepam, The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Pomalidomide.]
[D07AC08, fluocinonide, The metabolism of Pomalidomide can be increased when combined with Fluocinonide.]
[N06AA14, melitracen, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Melitracen.]
[H02AB03, fluocortolone, The metabolism of Pomalidomide can be increased when combined with Fluocortolone.]
[V03AZ01, ethanol, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[L01BC09, floxuridine, The risk or severity of adverse effects can be increased when Floxuridine is combined with Pomalidomide.]
[S01CB05, fluorometholone, The risk or severity of adverse effects can be increased when Fluorometholone is combined with Pomalidomide.]
[L01BC02, fluorouracil, The risk or severity of adverse effects can be increased when Fluorouracil is combined with Pomalidomide.]
[N06AB03, fluoxetine, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N05AF01, flupenthixol, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Pomalidomide.]
[N05AB02, fluphenazine, The risk or severity of adverse effects can be increased when Fluphenazine is combined with Pomalidomide.]
[N05CD01, flurazepam, The risk or severity of adverse effects can be increased when Flurazepam is combined with Pomalidomide.]
[S01BC04, flurbiprofen, Flurbiprofen may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N05AG01, fluspirilene, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Pomalidomide.]
[L02BB01, flutamide, The metabolism of Pomalidomide can be decreased when combined with Flutamide.]
[V04CX02, folic acid, Folic acid may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[S02AA17, fosfomycin, Fosfomycin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[S01AA07, framycetin, Framycetin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Pomalidomide.]
[M03AA01, alcuronium, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Alcuronium.]
[G01AX06, furazolidone, The risk or severity of adverse effects can be increased when Furazolidone is combined with Pomalidomide.]
[J05AE10, darunavir, The serum concentration of Pomalidomide can be increased when it is combined with Darunavir.]
[C03CA01, furosemide, Furosemide may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[M05BA04, alendronic acid, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Pomalidomide is combined with Alendronic acid.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Pomalidomide is combined with Eszopiclone.]
[N05AL05, amisulpride, The risk or severity of adverse effects can be increased when Amisulpride is combined with Pomalidomide.]
[M03AC02, gallamine, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Gallamine.]
[S01AD09, ganciclovir, Ganciclovir may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N03AA04, barbexaclone, The metabolism of Pomalidomide can be increased when combined with Barbexaclone.]
[N06AX08, bifemelane, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Bifemelane.]
[C10AB04, gemfibrozil, The metabolism of Pomalidomide can be decreased when combined with Gemfibrozil.]
[J01XA03, telavancin, Telavancin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[L01EA02, dasatinib, The metabolism of Pomalidomide can be decreased when combined with Dasatinib.]
[N04BC06, cabergoline, The risk or severity of adverse effects can be increased when Cabergoline is combined with Pomalidomide.]
[C01CA21, cafedrine, The metabolism of Cafedrine can be decreased when combined with Pomalidomide.]
[J05AG04, etravirine, The metabolism of Pomalidomide can be increased when combined with Etravirine.]
[N03AD03, methsuximide, The risk or severity of adverse effects can be increased when Methsuximide is combined with Pomalidomide.]
[N01AH02, alfentanil, The risk or severity of adverse effects can be increased when Alfentanil is combined with Pomalidomide.]
[L01EH01, lapatinib, The serum concentration of Pomalidomide can be increased when it is combined with Lapatinib.]
[A10BB01, glyburide, The metabolism of Pomalidomide can be decreased when combined with Glyburide.]
[A10BB07, glipizide, Glipizide may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N05CM18, dexmedetomidine, The metabolism of Pomalidomide can be decreased when combined with Dexmedetomidine.]
[N05CE01, glutethimide, The risk or severity of adverse effects can be increased when Glutethimide is combined with Pomalidomide.]
[C02CA04, doxazosin, The metabolism of Pomalidomide can be decreased when combined with Doxazosin.]
[L01EX02, sorafenib, The serum concentration of Pomalidomide can be increased when it is combined with Sorafenib.]
[M01CB04, aurothioglucose, Pomalidomide may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Pegaptanib may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[B01AA12, fluindione, The risk or severity of bleeding can be increased when Fluindione is combined with Pomalidomide.]
[C09AA09, fosinopril, Fosinopril may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[D01BA01, griseofulvin, The metabolism of Pomalidomide can be increased when combined with Griseofulvin.]
[S01EX01, guanethidine, Guanethidine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[L02AE03, goserelin, Goserelin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N05AD01, haloperidol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Pomalidomide.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Halothane is combined with Pomalidomide.]
[N05AH04, quetiapine, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.]
[N06BX13, idebenone, Pomalidomide may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[N02CX03, iprazochrome, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Iprazochrome.]
[L01CE02, irinotecan, The risk or severity of adverse effects can be increased when Irinotecan is combined with Pomalidomide.]
[N05CA21, allobarbital, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Allobarbital.]
[M04AA01, allopurinol, The risk or severity of adverse effects can be increased when Allopurinol is combined with Pomalidomide.]
[C09CA01, losartan, The metabolism of Pomalidomide can be decreased when combined with Losartan.]
[S01XA14, heparin, The risk or severity of bleeding can be increased when Heparin is combined with Pomalidomide.]
[G03DC01, allylestrenol, The metabolism of Pomalidomide can be decreased when combined with Allylestrenol.]
[A07EC02, mesalamine, Mesalazine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[C01CE02, milrinone, Milrinone may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[L01XX03, altretamine, The risk or severity of adverse effects can be increased when Altretamine is combined with Pomalidomide.]
[N05CA16, hexobarbital, The risk or severity of adverse effects can be increased when Hexobarbital is combined with Pomalidomide.]
[J05AG01, nevirapine, The metabolism of Pomalidomide can be decreased when combined with Nevirapine.]
[C08CA10, nilvadipine, The metabolism of Pomalidomide can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of bleeding can be increased when Nimesulide is combined with Pomalidomide.]
[C09AA04, perindopril, Perindopril may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[C02DB02, hydralazine, The metabolism of Pomalidomide can be decreased when combined with Hydralazine.]
[C03AA03, hydrochlorothiazide, Hydrochlorothiazide may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[R05DA03, hydrocodone, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[S02BA01, hydrocortisone, The metabolism of Pomalidomide can be increased when combined with Hydrocortisone.]
[C03AA02, hydroflumethiazide, Hydroflumethiazide may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[B05XA17, potassium acetate, Pomalidomide may decrease the excretion rate of Potassium acetate which could result in a higher serum level.]
[A12BA02, potassium citrate, Potassium citrate may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Hydroxocobalamin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[G04BD06, propiverine, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Propiverine.]
[P01BA02, hydroxychloroquine, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Pomalidomide.]
[N05AX07, prothipendyl, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Prothipendyl.]
[B05AA07, hetastarch, Pomalidomide may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[L01XX05, hydroxyurea, The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Pomalidomide.]
[N05BB01, hydroxyzine, Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.]
[J04AB04, rifabutin, The metabolism of Pomalidomide can be increased when combined with Rifabutin.]
[M05BA07, risedronic acid, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Pomalidomide is combined with Risedronic acid.]
[R02AX02, ibuprofen, Ibuprofen may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[B05XA08, sodium acetate, Pomalidomide may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[B05CB02, sodium citrate, The risk or severity of bleeding can be increased when Sodium citrate is combined with Pomalidomide.]
[L01DB06, idarubicin, The risk or severity of adverse effects can be increased when Idarubicin is combined with Pomalidomide.]
[L01AA06, ifosfamide, The metabolism of Pomalidomide can be increased when combined with Ifosfamide.]
[H01AC02, somatrem, The metabolism of Pomalidomide can be increased when combined with Somatrem.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Sufentanil is combined with Pomalidomide.]
[N06AA02, imipramine, The metabolism of Pomalidomide can be decreased when combined with Imipramine.]
[L01CD01, paclitaxel, The metabolism of Pomalidomide can be increased when combined with Paclitaxel.]
[R01AD07, tixocortol, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Tixocortol.]
[M03BX02, tizanidine, The metabolism of Pomalidomide can be decreased when combined with Tizanidine.]
[L01CE01, topotecan, The risk or severity of adverse effects can be increased when Topotecan is combined with Pomalidomide.]
[C03BA11, indapamide, Indapamide may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC01, indomethacin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Pomalidomide.]
[A11HA07, inositol, Pomalidomide may decrease the excretion rate of Inositol which could result in a higher serum level.]
[L03AB04, interferon alfa-2a, The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Pomalidomide.]
[L03AB05, interferon alfa-2b, The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Pomalidomide.]
[N06AX17, milnacipran, The metabolism of Pomalidomide can be decreased when combined with Milnacipran.]
[A03AA30, piperidolate, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[S01XA28, varenicline, Varenicline may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[L04AA25, eculizumab, The risk or severity of adverse effects can be increased when Eculizumab is combined with Pomalidomide.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Pomalidomide is combined with Articaine.]
[A10BH01, sitagliptin, The serum concentration of Pomalidomide can be increased when it is combined with Sitagliptin.]
[N05BA12, alprazolam, The risk or severity of adverse effects can be increased when Alprazolam is combined with Pomalidomide.]
[N05CH02, ramelteon, The risk or severity of adverse effects can be increased when Ramelteon is combined with Pomalidomide.]
[R06AE01, buclizine, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Buclizine.]
[C10AA06, cerivastatin, The metabolism of Pomalidomide can be increased when combined with Cerivastatin.]
[L01XX35, anagrelide, The metabolism of Pomalidomide can be decreased when combined with Anagrelide.]
[C07AA01, alprenolol, The risk or severity of adverse effects can be increased when Alprenolol is combined with Pomalidomide.]
[C03BA02, quinethazone, Quinethazone may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[L03AB09, interferon alfacon-1, The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Pomalidomide.]
[V03AB01, ipecac, Pomalidomide may decrease the excretion rate of Ipecac which could result in a higher serum level.]
[N06AA13, iprindole, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Iprindole.]
[N06AF05, iproniazid, The risk or severity of adverse effects can be increased when Iproniazid is combined with Pomalidomide.]
[J05AB13, penciclovir, The metabolism of Pomalidomide can be decreased when combined with Penciclovir.]
[N05AA07, chlorproethazine, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Chlorproethazine.]
[N06AF01, isocarboxazid, The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Pomalidomide.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Isoflurane is combined with Pomalidomide.]
[N04BX02, entacapone, The risk or severity of adverse effects can be increased when Entacapone is combined with Pomalidomide.]
[J04AC01, isoniazid, The metabolism of Pomalidomide can be decreased when combined with Isoniazid.]
[J05AX05, inosine pranobex, Pomalidomide may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[C01DA14, isosorbide mononitrate, Isosorbide mononitrate may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[D10BA01, isotretinoin, Isotretinoin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[B01AE06, bivalirudin, The risk or severity of bleeding can be increased when Bivalirudin is combined with Pomalidomide.]
[N06AX18, reboxetine, The risk or severity of adverse effects can be increased when Reboxetine is combined with Pomalidomide.]
[S01AA24, kanamycin, Pomalidomide may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[H01AC01, somatropin, The metabolism of Pomalidomide can be increased when combined with Somatotropin.]
[L04AC07, tocilizumab, The metabolism of Pomalidomide can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The risk or severity of adverse effects can be increased when Ketamine is combined with Pomalidomide.]
[C02KD01, ketanserin, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Ketanserin.]
[B01AC22, prasugrel, The risk or severity of bleeding can be increased when Prasugrel is combined with Pomalidomide.]
[J02AB02, ketoconazole, The metabolism of Pomalidomide can be decreased when combined with Ketoconazole.]
[H02CA04, levoketoconazole, The metabolism of Pomalidomide can be decreased when combined with Levoketoconazole.]
[N05AH03, olanzapine, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.]
[M02AA10, ketoprofen, Ketoprofen may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[V03AC03, deferasirox, The serum concentration of Pomalidomide can be increased when it is combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Pomalidomide can be increased when combined with Abatacept.]
[N04BC09, rotigotine, Pomalidomide may increase the sedative activities of Rotigotine.]
[D10AX03, azelaic acid, Azelaic acid may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[J01MB02, nalidixic acid, The metabolism of Pomalidomide can be decreased when combined with Nalidixic acid.]
[M01AE11, tiaprofenic acid, Tiaprofenic acid may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[C07AG01, labetalol, Labetalol may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N04BB01, amantadine, Amantadine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[A06AX03, lubiprostone, Lubiprostone may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N03AX18, lacosamide, The metabolism of Pomalidomide can be decreased when combined with Lacosamide.]
[C03CC01, ethacrynic acid, Etacrynic acid may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[L01DC03, mitomycin, The risk or severity of adverse effects can be increased when Mitomycin is combined with Pomalidomide.]
[N04BA01, levodopa, The risk or severity of adverse effects can be increased when Levodopa is combined with Pomalidomide.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Pomalidomide is combined with Lidocaine.]
[S01AA21, amikacin, Pomalidomide may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[N06BA13, armodafinil, The metabolism of Pomalidomide can be increased when combined with Armodafinil.]
[C03DB01, amiloride, Amiloride may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[N02CA07, lisuride, The risk or severity of adverse effects can be increased when Lisuride is combined with Pomalidomide.]
[N06AA07, lofepramine, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Lofepramine.]
[L01AD02, lomustine, The risk or severity of adverse effects can be increased when Lomustine is combined with Pomalidomide.]
[A07DA03, loperamide, The serum concentration of Pomalidomide can be increased when it is combined with Loperamide.]
[N05BA06, lorazepam, The risk or severity of adverse effects can be increased when Lorazepam is combined with Pomalidomide.]
[C10AA02, lovastatin, The metabolism of Pomalidomide can be decreased when combined with Lovastatin.]
[N05AH01, loxapine, The serum concentration of Pomalidomide can be increased when it is combined with Loxapine.]
[L01EG01, temsirolimus, The serum concentration of Pomalidomide can be increased when it is combined with Temsirolimus.]
[B05XA11, magnesium chloride, Pomalidomide may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, Pomalidomide may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Pomalidomide can be increased when used in combination with Magnesium sulfate.]
[L01BA05, pralatrexate, The risk or severity of adverse effects can be increased when Pralatrexate is combined with Pomalidomide.]
[L01EA03, nilotinib, The metabolism of Pomalidomide can be decreased when combined with Nilotinib.]
[V04CX04, mannitol, Mannitol may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA21, maprotiline, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Mazindol is combined with Pomalidomide.]
[C02BB01, mecamylamine, Mecamylamine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[L01AA05, mechlorethamine, The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Pomalidomide.]
[R06AE05, meclizine, The risk or severity of adverse effects can be increased when Meclizine is combined with Pomalidomide.]
[M02AA18, meclofenamic acid, Meclofenamic acid may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N05BA03, medazepam, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Medazepam.]
[P01BC02, mefloquine, The serum concentration of Pomalidomide can be increased when it is combined with Mefloquine.]
[C03BA05, mefruside, Mefruside may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AB06, nadroparin, The risk or severity of bleeding can be increased when Nadroparin is combined with Pomalidomide.]
[B01AB05, enoxaparin, The risk or severity of bleeding can be increased when Enoxaparin is combined with Pomalidomide.]
[B01AB04, dalteparin, The risk or severity of bleeding can be increased when Dalteparin is combined with Pomalidomide.]
[N05CH01, melatonin, The risk or severity of adverse effects can be increased when Melatonin is combined with Pomalidomide.]
[L01AA03, melphalan, The risk or severity of adverse effects can be increased when Melphalan is combined with Pomalidomide.]
[N06DX01, memantine, Memantine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N02AB02, meperidine, The metabolism of Pomalidomide can be decreased when combined with Meperidine.]
[N03AB04, mephenytoin, The risk or severity of adverse effects can be increased when Mephenytoin is combined with Pomalidomide.]
[N03AA01, mephobarbital, The metabolism of Pomalidomide can be increased when combined with Methylphenobarbital.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Pomalidomide is combined with Mepivacaine.]
[N05BC01, meprobamate, The risk or severity of adverse effects can be increased when Meprobamate is combined with Pomalidomide.]
[N02AX05, meptazinol, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Meptazinol.]
[G04BX16, tiopronin, Tiopronin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[L02BG01, aminoglutethimide, The metabolism of Pomalidomide can be increased when combined with Aminoglutethimide.]
[C03BC01, mersalyl, Mersalyl may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AC03, mesoridazine, The risk or severity of adverse effects can be increased when Mesoridazine is combined with Pomalidomide.]
[N05AX13, paliperidone, The serum concentration of Pomalidomide can be increased when it is combined with Paliperidone.]
[A10BA02, metformin, Metformin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[A04AA04, dolasetron, The risk or severity of adverse effects can be increased when Dolasetron is combined with Pomalidomide.]
[H01CB03, lanreotide, The metabolism of Pomalidomide can be decreased when combined with Lanreotide.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Pomalidomide.]
[N06BA03, methamphetamine, The risk or severity of adverse effects can be increased when Metamfetamine is combined with Pomalidomide.]
[A03AB07, methantheline, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, The risk or severity of adverse effects can be increased when Methapyrilene is combined with Pomalidomide.]
[N05CM01, methaqualone, The risk or severity of adverse effects can be increased when Methaqualone is combined with Pomalidomide.]
[J05AF05, lamivudine, Lamivudine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N03AA30, metharbital, The risk or severity of adverse effects can be increased when Metharbital is combined with Pomalidomide.]
[S01EC05, methazolamide, Methazolamide may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[G02CB05, metergoline, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Metergoline.]
[H03BB02, methimazole, The metabolism of Pomalidomide can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, The risk or severity of adverse effects can be increased when Pemetrexed is combined with Pomalidomide.]
[M03BA03, methocarbamol, The risk or severity of adverse effects can be increased when Methocarbamol is combined with Pomalidomide.]
[N05CA15, methohexital, The risk or severity of adverse effects can be increased when Methohexital is combined with Pomalidomide.]
[A11HA02, pyridoxine, Pyridoxine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N02BG08, ziconotide, The risk or severity of adverse effects can be increased when Ziconotide is combined with Pomalidomide.]
[L04AX03, methotrexate, The risk or severity of adverse effects can be increased when Methotrexate is combined with Pomalidomide.]
[N05AA02, methotrimeprazine, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[D05BA02, methoxsalen, The metabolism of Pomalidomide can be decreased when combined with Methoxsalen.]
[N02BG09, methoxyflurane, The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Pomalidomide.]
[C03AA08, methyclothiazide, Methyclothiazide may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AB01, methyldopa, Methyldopa may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[V04CG05, methylene blue, The serum concentration of Pomalidomide can be increased when it is combined with Methylene blue.]
[G02AB01, methylergonovine, The metabolism of Pomalidomide can be decreased when combined with Methylergometrine.]
[R03DA05, aminophylline, The metabolism of Pomalidomide can be decreased when combined with Aminophylline.]
[H02AB04, methylprednisolone, The metabolism of Pomalidomide can be increased when combined with Methylprednisolone.]
[N03AF03, rufinamide, The risk or severity of adverse effects can be increased when Rufinamide is combined with Pomalidomide.]
[G03EK01, methyltestosterone, Methyltestosterone may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N05CE02, methyprylon, The risk or severity of adverse effects can be increased when Methyprylon is combined with Pomalidomide.]
[N02CA04, methysergide, The metabolism of Pomalidomide can be decreased when combined with Methysergide.]
[A03FA01, metoclopramide, The risk or severity of sedation can be increased when Metoclopramide is combined with Pomalidomide.]
[C03BA08, metolazone, Metolazone may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB02, metoprolol, Metoprolol may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[P01AB01, metronidazole, The metabolism of Pomalidomide can be decreased when combined with Metronidazole.]
[V04CD01, metyrapone, The metabolism of Pomalidomide can be increased when combined with Metyrapone.]
[C01BB02, mexiletine, The metabolism of Pomalidomide can be decreased when combined with Mexiletine.]
[N06AX03, mianserin, The risk or severity of adverse effects can be increased when Mianserin is combined with Pomalidomide.]
[S02AA13, miconazole, The metabolism of Pomalidomide can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The metabolism of Pomalidomide can be decreased when combined with Aminophenazone.]
[B01AB07, parnaparin, The risk or severity of bleeding can be increased when Parnaparin is combined with Pomalidomide.]
[N05CD08, midazolam, The metabolism of Pomalidomide can be decreased when combined with Midazolam.]
[G03XB01, mifepristone, The serum concentration of Pomalidomide can be decreased when it is combined with Mifepristone.]
[B01AB10, tinzaparin, The risk or severity of bleeding can be increased when Tinzaparin is combined with Pomalidomide.]
[J05AH01, zanamivir, Zanamivir may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.]
[J01FA11, miocamycin, The metabolism of Pomalidomide can be decreased when combined with Miocamycin.]
[L01XX23, mitotane, The metabolism of Pomalidomide can be increased when combined with Mitotane.]
[L01DB07, mitoxantrone, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Pomalidomide.]
[N05AE02, molindone, The risk or severity of adverse effects can be increased when Molindone is combined with Pomalidomide.]
[L03AC01, aldesleukin, The metabolism of Pomalidomide can be decreased when combined with Aldesleukin.]
[C01BD01, amiodarone, The serum concentration of Pomalidomide can be increased when it is combined with Amiodarone.]
[N06AA09, amitriptyline, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Morphine is combined with Pomalidomide.]
[A04AA05, palonosetron, The risk or severity of adverse effects can be increased when Palonosetron is combined with Pomalidomide.]
[J01DD06, moxalactam, Latamoxef may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[L04AB05, certolizumab pegol, The metabolism of Pomalidomide can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The metabolism of Pomalidomide can be decreased when combined with Eltrombopag.]
[G04BA01, ammonium chloride, Ammonium chloride may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[L04AA52, ofatumumab, The risk or severity of adverse effects can be increased when Ofatumumab is combined with Pomalidomide.]
[L01EX03, pazopanib, The metabolism of Pomalidomide can be decreased when combined with Pazopanib.]
[L04AA06, mycophenolic acid, The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Pomalidomide.]
[M03AC03, vecuronium, The risk or severity of adverse effects can be increased when Vecuronium is combined with Pomalidomide.]
[N05CA02, amobarbital, The metabolism of Pomalidomide can be increased when combined with Amobarbital.]
[G04CA04, silodosin, The serum concentration of Pomalidomide can be increased when it is combined with Silodosin.]
[R03BB01, ipratropium bromide, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[G03XC01, raloxifene, The metabolism of Pomalidomide can be decreased when combined with Raloxifene.]
[N06AA17, amoxapine, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.]
[N03AB05, fosphenytoin, The metabolism of Pomalidomide can be increased when combined with Fosphenytoin.]
[L03AB08, interferon beta-1b, The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Pomalidomide.]
[C07AA12, nadolol, Nadolol may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[J01CA04, amoxicillin, Amoxicillin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N04BC04, ropinirole, Pomalidomide may increase the sedative activities of Ropinirole.]
[J01CF06, nafcillin, The metabolism of Pomalidomide can be increased when combined with Nafcillin.]
[C04AX21, nafronyl, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Naftidrofuryl.]
[N02AF02, nalbuphine, The risk or severity of adverse effects can be increased when Nalbuphine is combined with Pomalidomide.]
[V03AB15, naloxone, The metabolism of Pomalidomide can be decreased when combined with Naloxone.]
[L04AC03, anakinra, The metabolism of Pomalidomide can be increased when combined with Anakinra.]
[N06BA01, amphetamine, Amphetamine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[M02AA12, naproxen, The metabolism of Pomalidomide can be decreased when combined with Naproxen.]
[A10BG01, troglitazone, The metabolism of Pomalidomide can be increased when combined with Troglitazone.]
[N06AX21, duloxetine, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Tolcapone is combined with Pomalidomide.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Pomalidomide.]
[L01CD02, docetaxel, The metabolism of Pomalidomide can be decreased when combined with Docetaxel.]
[S03AA01, neomycin, Pomalidomide may decrease the excretion rate of Neomycin which could result in a higher serum level.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Remifentanil is combined with Pomalidomide.]
[B01AC17, tirofiban, The risk or severity of bleeding can be increased when Tirofiban is combined with Pomalidomide.]
[N05AX14, iloperidone, The risk or severity of adverse effects can be increased when Iloperidone is combined with Pomalidomide.]
[J02AA01, amphotericin B, Amphotericin B may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[S01AA19, ampicillin, Ampicillin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[L03AX16, plerixafor, Plerixafor may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[S01AA23, netilmicin, Pomalidomide may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, The metabolism of Pomalidomide can be decreased when combined with Desvenlafaxine.]
[J05AB11, valacyclovir, Valaciclovir may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[C01CE01, inamrinone, Amrinone may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[L01XX01, amsacrine, The risk or severity of adverse effects can be increased when Amsacrine is combined with Pomalidomide.]
[C10AD02, niacin, The metabolism of Pomalidomide can be decreased when combined with Niacin.]
[N06AF02, nialamide, The risk or severity of adverse effects can be increased when Nialamide is combined with Pomalidomide.]
[C08CA04, nicardipine, The metabolism of Pomalidomide can be decreased when combined with Nicardipine.]
[P02DA01, niclosamide, The metabolism of Pomalidomide can be decreased when combined with Niclosamide.]
[C08CA05, nifedipine, The metabolism of Pomalidomide can be decreased when combined with Nifedipine.]
[M02AA17, niflumic acid, Niflumic acid may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[C08CA07, nisoldipine, Nisoldipine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N05CD02, nitrazepam, The risk or severity of adverse effects can be increased when Nitrazepam is combined with Pomalidomide.]
[R07AX01, nitric oxide, Nitric Oxide may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[J01XE01, nitrofurantoin, Nitrofurantoin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N05CF03, zaleplon, The risk or severity of adverse effects can be increased when Zaleplon is combined with Pomalidomide.]
[N04BC05, pramipexole, Pomalidomide may increase the sedative activities of Pramipexole.]
[C02DD01, nitroprusside, Nitroprusside may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N01AX13, nitrous oxide, The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Pomalidomide.]
[N06AX04, nomifensine, The risk or severity of adverse effects can be increased when Nomifensine is combined with Pomalidomide.]
[G03DC02, norethindrone, The metabolism of Pomalidomide can be decreased when combined with Norethisterone.]
[S01AE02, norfloxacin, The metabolism of Pomalidomide can be decreased when combined with Norfloxacin.]
[C02KX01, bosentan, The metabolism of Pomalidomide can be increased when combined with Bosentan.]
[N06AA10, nortriptyline, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.]
[R05DA07, noscapine, The metabolism of Pomalidomide can be decreased when combined with Noscapine.]
[A16AX07, sapropterin, The serum concentration of Pomalidomide can be increased when it is combined with Sapropterin.]
[B01AC16, eptifibatide, The risk or severity of bleeding can be increased when Eptifibatide is combined with Pomalidomide.]
[L03AB07, interferon beta-1a, The metabolism of Pomalidomide can be decreased when combined with Interferon beta-1a.]
[B01AB08, reviparin, The risk or severity of bleeding can be increased when Reviparin is combined with Pomalidomide.]
[H01CB02, octreotide, The serum concentration of Pomalidomide can be increased when it is combined with Octreotide.]
[J01FA05, oleandomycin, The metabolism of Pomalidomide can be decreased when combined with Oleandomycin.]
[L04AC04, rilonacept, The metabolism of Pomalidomide can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Pomalidomide can be increased when combined with Omeprazole.]
[N06AA05, opipramol, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Opipramol.]
[N02AA02, opium, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Opium.]
[B01AD07, reteplase, The risk or severity of bleeding can be increased when Reteplase is combined with Pomalidomide.]
[B01AD09, ancrod, The risk or severity of bleeding can be increased when Ancrod is combined with Pomalidomide.]
[G04CA02, tamsulosin, Tamsulosin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[M05BA08, zoledronic acid, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Pomalidomide is combined with Zoledronic acid.]
[J01CF04, oxacillin, Oxacillin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N05BA04, oxazepam, The risk or severity of adverse effects can be increased when Oxazepam is combined with Pomalidomide.]
[C07AA02, oxprenolol, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Pomalidomide.]
[N02AA05, oxycodone, The risk or severity of adverse effects can be increased when Oxycodone is combined with Pomalidomide.]
[N02AA11, oxymorphone, The risk or severity of adverse effects can be increased when Oxymorphone is combined with Pomalidomide.]
[N05AE01, oxypertine, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Oxypertine.]
[S01BC02, oxyphenbutazone, Oxyphenbutazone may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[A03AB03, oxyphenonium, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[N05AH05, asenapine, The risk or severity of adverse effects can be increased when Asenapine is combined with Pomalidomide.]
[B01AB09, danaparoid, The risk or severity of bleeding can be increased when Danaparoid is combined with Pomalidomide.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.]
[M03AC01, pancuronium, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Pancuronium.]
[J04AB30, capreomycin, Pomalidomide may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[N05CC05, paraldehyde, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[H02AB05, paramethasone, The metabolism of Pomalidomide can be increased when combined with Paramethasone.]
[C02KC01, pargyline, The risk or severity of adverse effects can be increased when Pargyline is combined with Pomalidomide.]
[A07AA06, paromomycin, Paromomycin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[J01MA03, pefloxacin, The metabolism of Pomalidomide can be decreased when combined with Pefloxacin.]
[G04BD11, fesoterodine, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.]
[C07AA23, penbutolol, The risk or severity of adverse effects can be increased when Penbutolol is combined with Pomalidomide.]
[N05AG03, penfluridol, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Penfluridol.]
[M01CC01, penicillamine, The risk or severity of adverse effects can be increased when Penicillamine is combined with Pomalidomide.]
[J01CE09, penicillin G procaine, Pomalidomide may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.]
[J07AF01, diphtheria toxoid vaccine, inactivated, The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Pomalidomide.]
[J07AM01, tetanus toxoid vaccine, inactivated, The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Pomalidomide.]
[N02AD01, pentazocine, The risk or severity of adverse effects can be increased when Pentazocine is combined with Pomalidomide.]
[N05CA01, pentobarbital, The metabolism of Pomalidomide can be increased when combined with Pentobarbital.]
[L01XX08, pentostatin, The risk or severity of adverse effects can be increased when Pentostatin is combined with Pomalidomide.]
[C04AD03, pentoxifylline, The metabolism of Pomalidomide can be decreased when combined with Pentoxifylline.]
[N05AB10, perazine, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Perazine.]
[N04BC02, pergolide, The risk or severity of adverse effects can be increased when Pergolide is combined with Pomalidomide.]
[N05AB03, perphenazine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Pomalidomide.]
[J07AJ, pertussis vaccine, The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Pomalidomide.]
[N02BE03, phenacetin, The metabolism of Pomalidomide can be decreased when combined with Phenacetin.]
[N02AD02, phenazocine, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Phenazocine.]
[G04BX06, phenazopyridine, Phenazopyridine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N06AF03, phenelzine, The risk or severity of adverse effects can be increased when Phenelzine is combined with Pomalidomide.]
[B01AA02, phenindione, The risk or severity of bleeding can be increased when Phenindione is combined with Pomalidomide.]
[N03AA02, phenobarbital, The metabolism of Pomalidomide can be increased when combined with Phenobarbital.]
[N01AH04, phenoperidine, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Phenoperidine.]
[B01AA04, phenprocoumon, The risk or severity of bleeding can be increased when Phenprocoumon is combined with Pomalidomide.]
[V03AB36, phentolamine, Phentolamine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[M02AA01, phenylbutazone, The metabolism of Pomalidomide can be increased when combined with Phenylbutazone.]
[S01GA05, phenylephrine, The metabolism of Pomalidomide can be increased when combined with Phenylephrine.]
[N03AB02, phenytoin, The metabolism of Pomalidomide can be increased when combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Pomalidomide can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, Levofloxacin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[L02BB03, bicalutamide, The metabolism of Pomalidomide can be decreased when combined with Bicalutamide.]
[B02BA01, vitamin K1, Phylloquinone may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[J05AB12, cidofovir, Cidofovir may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[C08CX01, mibefradil, The serum concentration of Pomalidomide can be increased when it is combined with Mibefradil.]
[N05AG02, pimozide, The metabolism of Pomalidomide can be decreased when combined with Pimozide.]
[C07AA03, pindolol, The risk or severity of adverse effects can be increased when Pindolol is combined with Pomalidomide.]
[J01CA12, piperacillin, Piperacillin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[J05AE01, saquinavir, The metabolism of Pomalidomide can be decreased when combined with Saquinavir.]
[N05AC04, pipothiazine, The risk or severity of adverse effects can be increased when Pipotiazine is combined with Pomalidomide.]
[N06BX03, piracetam, Pomalidomide may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[A02BX03, pirenzepine, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N02AC03, pirinitramide, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Piritramide.]
[S01BC06, piroxicam, Piroxicam may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[J01DD16, cefditoren, Cefditoren may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[J01MA11, grepafloxacin, The metabolism of Pomalidomide can be decreased when combined with Grepafloxacin.]
[N02CX01, pizotyline, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.]
[J05AG02, delavirdine, The metabolism of Pomalidomide can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Pomalidomide can be decreased when combined with Irbesartan.]
[N05CA22, proxibarbal, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Proxibarbal.]
[B01AC13, abciximab, The risk or severity of bleeding can be increased when Abciximab is combined with Pomalidomide.]
[S01XA13, alteplase, The risk or severity of bleeding can be increased when Alteplase is combined with Pomalidomide.]
[A10BG02, rosiglitazone, Rosiglitazone may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[A03AE01, alosetron, The metabolism of Pomalidomide can be decreased when combined with Alosetron.]
[L04AC08, canakinumab, The metabolism of Pomalidomide can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, Polythiazide may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE03, ritonavir, The serum concentration of Pomalidomide can be increased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, Saxagliptin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[B05XA01, potassium chloride, Potassium chloride may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N05BA11, prazepam, The risk or severity of adverse effects can be increased when Prazepam is combined with Pomalidomide.]
[P02BA01, praziquantel, The metabolism of Pomalidomide can be decreased when combined with Praziquantel.]
[S03BA02, prednisolone, The metabolism of Pomalidomide can be increased when combined with Prednisolone.]
[H02AB07, prednisone, The risk or severity of adverse effects can be increased when Prednisone is combined with Pomalidomide.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Pomalidomide is combined with Prilocaine.]
[P01BA03, primaquine, The metabolism of Pomalidomide can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Pomalidomide can be increased when combined with Primidone.]
[M04AB01, probenecid, The metabolism of Pomalidomide can be increased when combined with Probenecid.]
[C01BA02, procainamide, Pomalidomide may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Pomalidomide is combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Procarbazine is combined with Pomalidomide.]
[C10AB05, fenofibrate, The metabolism of Pomalidomide can be decreased when combined with Fenofibrate.]
[N05AB04, prochlorperazine, The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pomalidomide.]
[N04AA04, procyclidine, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.]
[N05AA03, promazine, The metabolism of Pomalidomide can be decreased when combined with Promazine.]
[R06AD02, promethazine, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Promethazine.]
[C01BC03, propafenone, The serum concentration of Pomalidomide can be increased when it is combined with Propafenone.]
[N01AX04, propanidid, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Propanidid.]
[A03AB05, propantheline, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[R06AX26, fexofenadine, The serum concentration of Pomalidomide can be increased when it is combined with Fexofenadine.]
[N05AC01, periciazine, The risk or severity of adverse effects can be increased when Periciazine is combined with Pomalidomide.]
[N05CM06, propiomazine, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Propiomazine.]
[L01XH02, romidepsin, The serum concentration of Pomalidomide can be increased when it is combined with Romidepsin.]
[N01AX10, propofol, The metabolism of Pomalidomide can be decreased when combined with Propofol.]
[N02AC04, propoxyphene, The metabolism of Pomalidomide can be decreased when combined with Dextropropoxyphene.]
[C07AA05, propranolol, The metabolism of Pomalidomide can be decreased when combined with Propranolol.]
[H03BA02, propylthiouracil, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Pomalidomide.]
[N02CC04, rizatriptan, The risk or severity of adverse effects can be increased when Rizatriptan is combined with Pomalidomide.]
[B01AC09, epoprostenol, The risk or severity of bleeding can be increased when Epoprostenol is combined with Pomalidomide.]
[N06AA11, protriptyline, The risk or severity of adverse effects can be increased when Protriptyline is combined with Pomalidomide.]
[N05AX12, aripiprazole, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.]
[N07XX07, dalfampridine, Dalfampridine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[A03AB15, diphemanil, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, The risk or severity of adverse effects can be increased when Talbutal is combined with Pomalidomide.]
[N05CA09, vinbarbital, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Vinbarbital.]
[N05BB02, captodiamine, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Captodiame.]
[M03BA04, styramate, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Styramate.]
[P02CC01, pyrantel, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Pyrantel.]
[J04AK01, pyrazinamide, Pyrazinamide may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[J06BB05, rabies immune globulin, human, The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Pomalidomide.]
[R06AC01, pyrilamine, The risk or severity of adverse effects can be increased when Mepyramine is combined with Pomalidomide.]
[C01BA01, quinidine, The serum concentration of Pomalidomide can be increased when it is combined with Quinidine.]
[P01BC01, quinine, The serum concentration of Pomalidomide can be increased when it is combined with Quinine.]
[A02BA02, ranitidine, The metabolism of Pomalidomide can be decreased when combined with Ranitidine.]
[C02AA02, reserpine, The serum concentration of Pomalidomide can be increased when it is combined with Reserpine.]
[J05AP01, ribavirin, Ribavirin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[J04AB02, rifampin, The serum concentration of Pomalidomide can be decreased when it is combined with Rifampicin.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of adverse effects can be increased when Oxitriptan is combined with Pomalidomide.]
[J01FA06, roxithromycin, The metabolism of Pomalidomide can be decreased when combined with Roxithromycin.]
[N02BA05, salicylamide, Salicylamide may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[A07EC01, sulfasalazine, The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Pomalidomide.]
[S01BC08, salicylic acid, Salicylic acid may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[S01FA02, scopolamine, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CA06, secobarbital, The metabolism of Pomalidomide can be increased when combined with Secobarbital.]
[N04BD01, selegiline, The risk or severity of adverse effects can be increased when Selegiline is combined with Pomalidomide.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Obinutuzumab.]
[J01GB08, sisomicin, Pomalidomide may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Pomalidomide may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[M05BX04, denosumab, The risk or severity of adverse effects can be increased when Denosumab is combined with Pomalidomide.]
[H01CB01, somatostatin, The metabolism of Pomalidomide can be decreased when combined with Somatostatin.]
[V04CC01, sorbitol, Sorbitol may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[L01CD04, cabazitaxel, The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pomalidomide.]
[L03AX17, sipuleucel-T, The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pomalidomide.]
[C03DA01, spironolactone, Spironolactone may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AG01, valproic acid, The metabolism of Pomalidomide can be decreased when combined with Valproic acid.]
[M05BA01, etidronic acid, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Pomalidomide is combined with Etidronic acid.]
[D07AB02, hydrocortisone butyrate, The metabolism of Pomalidomide can be increased when combined with Hydrocortisone butyrate.]
